



Open Access

16th International Symposium on HIV and Emerging Infectious Diseases

Marseille, France
24-26 March 2010

<http://www.retrovirology.com/supplements/7/S1>

II-I32 – Invited speaker presentations

O1-O16 – Oral presentations

P1-P192 – Poster presentations

Editor-in-chief
Kuan-Teh Jeang

Retrovirology (<http://www.retrovirology.com>) is an open access journal published by BioMed Central Ltd. The journal publishes stringently peer-reviewed, high-impact articles on basic retrovirus research. *Retrovirology* (ISSN 1742-4690) is indexed/tracked/covered by PubMed Central, MEDLINE, Thomson Reuters (ISI), Biosis, CAS, CABI, Embase and Current Contents.

Contact BioMed Central
supplements@
biomedcentral.com

www.isheid.com

16th

isheid

HIV & Emerging Infectious Diseases
VIH & Maladies Infectieuses Emergentes


International Symposium
Symposium International

24 ▶ 26

March/Mars **2010**

Parc Chanot

Marseille, France



FINAL PROGRAMME
PROGRAMME FINAL

Committees / Comités.....	p. 02
Welcome Address / Message de bienvenue.....	p. 03
General Information / Informations générales.....	p. 04
Parc Chanot map / Plan du Parc Chanot.....	p. 09
Programme at a glance / Synopsis.....	p. 12
Wednesday 24 March / Mercredi 24 mars.....	p. 14
Thursday 25 March / Jeudi 25 mars.....	p. 18
Friday 26 March / Vendredi 26 mars.....	p. 22
Posters / Communications affichées.....	p. 28
Authors index / Liste des auteurs.....	p. 49
Industry satellite symposia / Symposia satellites de l'industrie.....	p. 59
Exhibition / Exposition.....	p. 60
Sponsors / Partenaires.....	p. 62

COMMITTEES / COMITÉS

2010 Chairman / Président

- ▶ Alain LAFEUILLADE (France)

2010 Steering Committee / Comité d'organisation 2010

- ▶ Jean-François DELFRAISSY (France)
- ▶ Jose GATELL (Spain)
- ▶ Guido POLI (Italy)
- ▶ Christine ROUZIUX (France)
- ▶ Vicente SORIANO (Spain)
- ▶ Hans-J. STELLBRINK (Germany)
- ▶ Stefano VELLA (Italy)

2010 Scientific Committee / Comité Scientifique 2010

- ▶ Antoine CHERET (France)
- ▶ Patricia ENEL (France)
- ▶ Robert GALLO (USA)
- ▶ Gilles HITTINGER (France)
- ▶ Leondios KOSTRIKIS (Cyprus)
- ▶ John KALDOR (Australia)
- ▶ Denis LACOSTE (France)
- ▶ Mark NELSON (UK)
- ▶ Cecile POGGI (France)
- ▶ Isabelle POIZOT-MARTIN (France)
- ▶ Alain RIEU (France)
- ▶ Paolo RIZZARDI (Italy)
- ▶ Jurgen ROCKSTROH (Germany)
- ▶ Caroline SOLAS (France)
- ▶ Catherine TAMALET (France)
- ▶ Giuseppe TAMBUSI (Italy)
- ▶ Jean-Claude TARDY (France)

WELCOME ADDRESS MESSAGE DE BIENVENUE

Welcome to the 16th ISHEID!

I have the pleasure to welcome you to this new edition of the "International Symposium on HIV & Emerging Infectious Diseases", held for the first time in Marseille.

As you are aware, over the last 15 years, this event grew from a local meeting to an internationally renowned congress. It is henceforth the stage welcoming the most distinguished experts, allowing fruitful exchanges, and addressing the most exciting topics in the fields of HIV, hepatitis viruses and emerging pathogens.

The ISHEID principles are primarily driven by science and by the need to offer a better clinical care to our patients. This is why the Steering Committee and the Scientific Committee are keen to offer a cutting edge program in all sessions, including the satellite symposia. I would like to thank particularly all the members of these Committees who helped me building this captivating program, and all the speakers who agreed to be part of it. I also thank all the participants for the increased number of abstracts submitted this year. This led to tough selection choices for oral presentations, but also to a high quality in the poster sessions.

This year, the new location of Marseille allows better accommodation and accessibility than in the past: we hope that you will appreciate this choice and keep some extra time to discover this charming city.

Kindest regards;

Alain Lafeuillade, MD, On behalf of the Steering Committee

Alain Lafeuillade

Bienvenue au 16^{ème} ISHEID !

Au nom du Comité d'Organisation, j'ai le plaisir de vous accueillir à cette édition du « Symposium International sur le VIH et les Maladies Infectieuses Emergentes » qui se tient pour la première fois à Marseille.

Ce congrès a évolué sur les 15 dernières années d'une manifestation régionale à un rassemblement scientifique de renommée internationale. Il est la scène sur laquelle vous rencontrez les experts les plus avertis, où les sujets les plus « brûlants » sont traités, dans les domaines du VIH, des hépatites virales, et des infections émergentes. Sa dimension permet au congrès d'assurer des échanges fructueux directs entre participants et experts.

Les préoccupations essentielles de l'ISHEID sont scientifiques, ainsi que le besoin d'apporter à nos patients une meilleure prise en charge. C'est pourquoi nous avons veillé à la haute tenue du programme au sein de toutes les sessions, y compris les symposia satellites. Je tiens à ce propos à remercier les membres des Comités d'Organisation et Scientifique qui m'ont aidé à construire un programme riche et captivant, et l'ensemble des orateurs qui ont accepté d'y intervenir. Je remercie également les participants pour avoir soumis un nombre accru de résumés cette année, avec une qualité toujours croissante. Cela a eu, paradoxalement, l'effet de conduire à des choix difficiles dans la sélection finale.

Cette année, la ville de Marseille permet aussi une meilleure accessibilité et un choix plus complet d'hôtels. J'espère que vous saurez apprécier cette nouvelle destination et lui consacrez aussi un peu de temps.

En vous souhaitant un bon congrès ;

Dr Alain Lafeuillade, au nom du Comité d'Organisation

Alain Lafeuillade

GENERAL INFORMATION INFORMATIONS GÉNÉRALES

DATES & LOCATION / DATES ET LIEU



The 16th ISHEID congress will be held from Wednesday 24 March to Friday 26 March 2010 and will take place at:

Le 16^{ème} congrès ISHEID se tiendra du mercredi 24 mars au vendredi 26 mars 2010 au :

PARC CHANOT DE MARSEILLE
BP 2 - 13266 Marseille Cedex 08
www.parc-chanot.com

ACCESS TO THE PARC CHANOT / ACCÈS AU PARC CHANOT



► **By metro / En métro**

From Saint Charles station:
13 minutes.

Direction: Sainte Marguerite.

Exit station « Rond Point du Prado ».

More information: www.rtm.fr

A partir de la Gare Saint Charles :
13 minutes.

Direction : Sainte Marguerite.

Sortie station « Rond Point du Prado ».

Pour plus d'information : www.rtm.fr

Taxi from station / Taxi gare

Tel : +33 (0)4 91 02 20

BADGE

A name badge will be provided on-site with your registration documents. The wearing of this badge is compulsory both inside the conference rooms and in the exhibition area.

Un badge nominatif vous sera remis sur place accompagné de vos documents de congrès. Le port du badge est obligatoire dans l'ensemble des salles de conférences et à la zone d'exposition.

Colour code / Code couleur

Delegates / Participants **white / blanc**

Speakers / Orateurs **turquoise**

Exhibitors / Exposants **purple / violet**

Organisation **red / rouge**

IMPORTANT: Always keep your badge after ISHEID. You will need to remove your certificate functions of CME credits.

IMPORTANT : pensez à conserver votre badge à l'issue d'ISHEID. Il vous sera indispensable pour retirer votre attestation d'attributions de points CME.

CELLULAR PHONES / TÉLÉPHONES PORTABLES

Thank you for not using your cell phone in conference rooms.

Nous vous remercions de ne pas utiliser votre téléphone portable dans les salles de conférence.

CERTIFICATES OF ATTENDANCE / CERTIFICATS DE PRÉSENCE

Certificates of attendance will be issued to pre-registered delegates during the withdrawal of their badge.

Registered delegates on site will receive this certificate upon registration.

Les certificats de présence seront remis à chaque participant pré-inscrit lors du retrait de leur badge.

Les participants inscrits sur place se verront remettre ce certificat lors de leur inscription.

CLOAKROOM / VESTIAIRE

A free cloakroom is at participant's disposal during the welcome desk opening hours. It is located on level 2, hall des pas perdus.

Please make sure that no personal belongings are left after closing each day.

Un vestiaire gratuit est à la disposition des participants pendant les heures d'ouverture de l'accueil. Il est situé au niveau 2, hall des pas perdus.

Veuillez vous assurer qu'aucun effet personnel n'est laissé après la clôture de chaque jour.

CME CREDITS / CRÉDITS CME

The 16th International Symposium on HIV and Emerging Infectious Diseases is accredited by the European Accreditation Council for Continuing Medical Education

(EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.net.

The 16th International Symposium on HIV and Emerging Infectious Diseases is designated for a maximum of (or for up to) 18 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA: www.accme.org.

Le 16^{ème} ISHEID est accrédité par l'EACCME (European Accreditation Council for Continuing Medical Education) concernant les activités de CME (Continuing Medical Education) pour les médecins spécialistes. L'EACCME est une institution de l'UEMS (European Union of Medical Specialists) : www.uems.net.

Le 16^{ème} ISHEID est prévu pour un maximum de 18 heures de crédits CME externes européens. Les médecins spécialistes ne peuvent se prévaloir que des heures qu'ils ont effectivement passées dans une activité éducative.

Le système de crédits CME est basé sur 1 crédit CME par heure avec un maximum de 3 crédits CME pour une demi-journée et 6 crédits pour une journée entière.

Les crédits EACCME sont reconnus par l'AMA (American Medical Association towards the Physician's Recognition Award). Afin de convertir un crédit EACCME en AMAPRA catégorie 1, prière de contacter l'AMA : www.accme.org.

The certificates will be issued the week following the conference via the website: www.isheid.com

Access will be using your last name, first name and number on your badge (think of keeping it after the conference).

Les attestations seront délivrées la semaine suivant le congrès via le site Internet :

www.isheid.com

L'accès se fera à l'aide de votre nom, prénom et du numéro figurant sur votre badge (penser à garder celui-ci après le congrès).

COFFEE BREAKS / PAUSES CAFÉS

Coffee breaks will take place in the exhibition area with the support of Gilead.

Les pauses-café auront lieu sur la zone d'exposition avec le soutien de Gilead.

CONGRESS SECRETARIAT / SECRÉTARIAT DU CONGRÈS

During the meeting / Durant le congrès

PARC CHANOT

Information and registration desks:

Level 2, Hall des pas perdus

Information et bureau des inscriptions :

Niveau 2, Hall des pas perdus

OPENING HOURS / HEURES D'OUVERTURE

Wednesday 24 March / Mercredi 24 mars :

08:00 - 19:30

Thursday 25 March / Jeudi 25 mars :

07:30 - 18:30

Friday 26 March / Vendredi 26 mars :

07:30 - 17:00

After the meeting / Après le congrès

ISHEID 2010 c/o Colloquium

12 rue de la Croix-Faubin

75 557 Paris Cedex 11

Tel: + 33 (0)1 44 64 15 15

Fax: + 33 (0)1 44 64 15 16

E-mail: isheid@clq-group.com

CURRENCY / MONNAIE

The national currency in France is the EURO (1 Euro= 100 Cents). Coins of 1, 2 and 5 Cents are copper-coloured; coins of 10, 20 and 50 Cents are gold-coloured; 1 and 2 Euro coins are gold-and-silver coloured. Euro notes come in denominations of 5, 10, 20, 50, 100, 200 and 500. Credit cards as well as most major currencies are widely accepted. For currency exchange, please ask your hotel for further information.

La monnaie nationale en France est l'EURO (1 euro = 100 cents). Les pièces de 1, 2 et 5 Centimes sont cuivrées ; les pièces de 10, 20 et 50 Centimes sont dorées ; les pièces de 1 et 2 Euro sont dorées et argentées. Les billets en Euro comportent des coupures de 5, 10, 20, 50, 100, 200 et 500. Les cartes de crédit de même que la plupart des monnaies principales sont largement acceptées. Pour changer de l'argent, merci de vous adresser à votre hôtel.

GENERAL INFORMATION INFORMATIONS GÉNÉRALES

CYBER-SPACE / CYBER-ESPACE

A cyber-space is located in the exhibition area, next to the Tibotec booth. Computers stations will be at your disposal for your internet connections.

Un cyber-espace est situé dans la zone d'exposition à côté du stand Tibotec. Des ordinateurs sont à votre disposition pour vos connexions internet.

ELECTRICITY / ELECTRICITÉ

The electrical supply in most areas of France is 220 V, 50 Hz. Plug sockets are European continental standard (two round pins).

La charge électrique dans la plupart des régions de France est 220 V, 50 Hz. Les prises électriques sont au standard européen continental (prise ronde bipolaire).

EXHIBITION / EXPOSITION

Located at Level 2, the exhibition is open every day of the conference. It allows you to develop and enrich your communication with our partners and discover their products.

Située au niveau 2, l'exposition est ouverte tous les jours du congrès. Elle vous permet de développer et enrichir vos échanges avec nos partenaires et de découvrir leurs produits.

OPENING HOURS / HORAIRES D'OUVERTURES

Wednesday 24 March / Mercredi 24 mars :
08:00 - 19:30

Thursday 25 March / Jeudi 25 mars :
07:30 - 18:30

Friday 26 March / Vendredi 26 mars :
07:30 - 17:00

INSURANCE POLICY / ASSURANCE ET RESPONSABILITÉ

The Symposium Organiser can not accept liability for personal injury, loss of or damage to belongings of Symposium participants, either during or as a result of the Symposium. Please check the validity of your own insurance.

L'organisateur du Symposium ne peut être rendu responsable en cas de dommages aux personnes, de pertes ou de dommages aux effets des participants du Symposium, ni pendant, ni après celui-ci. Merci de vérifier la validité de votre propre assurance.

LANGUAGE / LANGUES

The official congress language is English except for sessions where a French flag appears on the programme.

Headsets will be distributed at the entrance of the Congress Hall, in exchange for the voucher which is in your delegate pack.

La langue officielle du congrès est l'anglais excepté les sessions où un drapeau français apparaît sur le programme.

Les casques de traductions sont distribués à l'accueil en échange de votre bon d'échange qui est dans votre dossier congressiste.

LOST AND FOUND / OBJETS TROUVÉS

Lost items should be returned to the Congress Information desk (level 2, hall des pas perdus) which is at your disposal in case of loss of items.

Les objets trouvés doivent être retournés à la banque d'information de l'accueil (Niveau 2, hall des pas perdus) qui se tient à votre disposition en cas de perte d'objet.

POSTERS / COMMUNICATIONS AFFICHÉES

Posters are located in the Goudes Room, level 2 / Les communications affichées sont situées dans la salle les Goudes, niveau 2.

Opening hours / Horaires d'ouvertures :

Wednesday 24 March / Mercredi 24 mars:
09:00-19:30

Thursday 25 March / Jeudi 25 mars:
07:30-18:30

Friday 26 March / Vendredi 26 mars:
07:30-15:30.

The best poster will be awarded on Friday, March 26 at 10:30 at the end of the plenary session in the Auditorium.

Le prix du meilleur poster sera remis le vendredi 26 mars à 10h30 à la fin de la plénière dans l'Auditorium.

PROGRAMME CHANGES / CHANGEMENTS DANS LE PROGRAMME

The organisers cannot assume liability for any changes in the programme due to external or unforeseen circumstances.

Les organisateurs n'assument aucune responsabilité pour des changements dans le programme qui seraient dus à des circonstances extérieures ou imprévisibles.

PUBLICATION OF ABSTRACTS / PUBLICATION DES ABSTRACTS

All accepted abstracts are published on the CD-Rom that will be given at Gilead booth number 7 upon presentation of the voucher included in the congress bag.

All accepted abstracts will be published also after the congress in "Retrovirology":
<http://retrovirology.com>

Les résumés acceptés sont publiés sur le CD-Rom qui vous sera remis sur le stand de Gilead, numéro 7, sur présentation du voucher situé dans la sacoche. Les résumés acceptés seront également publiés après le congrès dans « Retrovirology » :

<http://retrovirology.com>

SMOKING POLICY / TABAC

It is forbidden to smoke anywhere in the Parc Chanot.

Il est interdit de fumer dans l'ensemble des espaces du Parc Chanot.

SPEAKER PREVIEW ROOM / SALLE DES ORATEURS

The speaker preview room is located in the Morgiou Room, level 2 at the Parc Chanot.

La salle des orateurs est située dans la salle Morgiou, niveau 2 du Parc Chanot.

Speakers please proceed to the preview room

- At last 1 hour before the session for MORNING presentations
- Between 9:00 am and 12:00 am on the day of the session for AFTERNOON presentations.

Les orateurs sont priés de se rendre en salle de pré-projection

- Au moins une heure avant la session pour les présentations du matin
- Entre 9 :00 et 12 :00 le jour de la session pour les présentations de l'après-midi.

USEFUL WEB SITES / SITES UTILES

ISHEID 2010:

www.isheid.com

Venue / Centre de conférence :

www.parc-chanot.com

Tourism / Office de tourisme :

www.marseille-tourisme.com

National airline company /

Compagnie aérienne nationale :

www.airfrance.fr

National train network / Réseau ferré national :

www.sncf.fr

Metro, bus in Marseille /Métro, bus dans Marseille :

www.rtm.fr

WELCOME RECEPTION / COCKTAIL DE BIENVENUE

The Welcome Reception on Wednesday 24 March 2010 will take place from 18:30 to 19:30 in the exhibition area.

Le cocktail de bienvenue aura lieu le mercredi 24 mars 2010 de 18:30 à 19:30 dans l'exposition.

GENERAL INFORMATION INFORMATIONS GENERALES

CONGRESS REGISTRATION & CANCELLATION CONDITIONS / INSCRIPTIONS CONGRÈS ET CONDITIONS D'ANNULATIONS

All rates are in Euros, French VAT 19,6% included/ Tous les tarifs sont exprimés en euros TTC.

Inscriptions sur place/Registration on site

Participant	460€
Reduced rate* / Tarif réduit*	110€

Reduced rate applicable to the following categories:

- ▶ AIDS Association Member
- ▶ Students / Residents (please present a copy of your student card).
- ▶ Low and Middle income countries (World Bank List <http://go.worldbank.org/K2CKM78CCO>)
- ▶ Nurses

Le tarif réduit est applicable aux catégories suivantes :

- ▶ Membres d'associations de lutte contre le SIDA
- ▶ Etudiants et internes (Sur envoi d'un justificatif : photocopie de la carte d'étudiant pour l'année en cours)
- ▶ Pays à faible et moyen revenus (World Bank List <http://go.worldbank.org/K2CKM78CCO>)
- ▶ Infirmier(e)s

CANCELLATION POLICY FOR INDIVIDUAL REGISTRATIONS / CONDITIONS D'ANNULATION INSCRIPTIONS INDIVIDUELLES

All cancellations must be notified in writing to: / Toutes annulations doivent être notifiées par écrit à :

ISHEID 2010 c/o Colloquium
12 rue de la Croix-Faubin
75 011 Paris, France

Fax : + 33 1 44 64 15 16
E-mail : isheid@clq-group.com

▶ **AFTER JANUARY, 15: NO REFUND.** With no payment received before that date, the total amount will still remain due to the Congress office. / En l'absence de paiement reçu avant cette date, le montant total restera dû au secrétariat du Congrès.

▶ **APRÈS LE 15 JANVIER : AUCUN REMBOURSEMENT** All refunds will be issued after the congress. Requests will not be accepted after the 30 April 2010. / Tous les remboursements seront effectués après le congrès et aucune demande ne sera traitée après le 30 avril 2010.

ACCOMMODATION/ HÉBERGEMENT

WIP is the official hotel reservation centre in charge of accommodation for the 2010 ISHEID Congress.

WIP est la centrale de réservation hôtelière officielle pour la gestion de l'hébergement du congrès ISHEID 2010.

For any information please contact / Pour toute information, veuillez contacter :

Marie Cohade

Tel : 33 1 70 36 04 25 - E-mail : m.cohade@wipresa.com


REGISTRATION FEES INCLUDE / LES DROITS D'INSCRIPTION INCLUENT :

- ▶ Name Badge / Badge nominatif
- ▶ Admission to all congress sessions, poster area and exhibition area from Wednesday 24 March to Friday 26 March / la participation aux sessions du congrès, aux présentations posters et à la zone d'exposition du mercredi 24 mars au vendredi 26 mars.
- ▶ Invitation to the welcome reception / Invitation au cocktail de bienvenue
- ▶ Congress documents (congress bag, final programme, Abstracts CD-Rom, writing pads and pens) / les documents du congrès (sacoche, programme final, CD-Rom des abstracts, blocs-notes et stylos)
- ▶ Coffee breaks from Wednesday 24 March to Friday 26 March / les pauses café du mercredi 24 mars au vendredi 26 mars.

Please note that no funds are available for scholarships / Aucune bourse ou subvention ne sera accordée.

PARC CHANOT MAP PLAN DU PARC CHANOT

LEVEL 2 NIVEAU 2



A series of horizontal dashed lines for writing, spanning the width of the page.

PROGRAMME AT A GLANCE SYNOPSIS

WEDNESDAY 24 MARCH 2010

	Auditorium	Amphitheater Callelongue
9:30	Plenary Session Emerging Infectious Diseases	
11:00	Coffee break sponsored by Gilead	
11:30	Parallel Sessions Long Term HIV Management (I)	Parallel Sessions Pharmacology of HIV
13:00	Session COREVIH In French only	Industry Satellite Symposium Schering Plough Shaping the Future of HIV-HCV Co-infected Patients
14:00	Plenary Session Immunology of HIV	
15:30	Coffee break sponsored by Gilead	
16:00	Keynote Lecture by Robert GALLO 25 Years after Discovering HIV as the Cause of AIDS: Prospects for a Vaccine	
17:00	Industry Satellite Symposium MSD Steering for New Strategies	
18:30		

THURSDAY 25 MARCH 2010

	Auditorium	Amphitheater Callelongue
8:30	Plenary Session HIV Reservoirs & Primary Infection	
10:30	Coffee break sponsored by Gilead	
11:00	Parallel Sessions HIV Resistance	Parallel Sessions Free Oral Presentations (I)
12:30	Industry Satellite Symposium Tibotec Janssen-Cilag Switching from Stable Regimen: Which Risks, Which Benefits?	
14:00	Plenary Session Antiretroviral Strategies	
15:30	Coffee break sponsored by Gilead	
16:00	Keynote Lecture by Albert OSTERHAUS The Global Challenge of Emerging Infectious Diseases	
17:00	Industry Satellite Symposium Abbot Virology HIV, a Chronic Disease: what Priorities to manage?	
18:30		

FRIDAY 26 MARCH 2010

	Auditorium	Amphitheater Callelongue
8:30	Plenary Session Co-Infections	
10:30	Coffee break sponsored by Gilead	
11:00	Parallel Sessions HIV Controllers	Parallel Sessions Free Oral Presentations (II)
12:30	Parallel Sessions Long Term HIV Management (II) with the support of Bristol Myers Squibb	Parallel Sessions Discussed Posters
14:00	Parallel Sessions Towards an HIV Vaccine	Parallel Sessions Post-CROI
15:00	Coffee break sponsored by Gilead	
15:30	Reporter Session	
16:30		

MERCREDI 24 MARS 2010

9:30	Auditorium	Amphithéâtre Callelongue
	Session Plénière	
11:00	Maladies Infectieuses Émergentes	
11:30	Pause - café sponsorisée par Gilead	
13:00	Sessions Parallèles Gestion à Long Terme de l'Infection à VIH (I)	Sessions Parallèles VIH, Session Pharmacologique
14:00	Session COREVIH En français seulement	Symposium Satellite de l'Industrie Schering Plough Modeler l'Avenir des Patients Co-infectés VIH-VHC
15:30	Session Plénière Immunologie du VIH	
16:00	Pause - café sponsorisée par Gilead	
17:00	Conférence Plénière par Robert GALLO 25 Ans après avoir découvert le VIH comme Agent Causal du SIDA : Recherche d'un Vaccin	
18:30		Symposium Satellite de l'Industrie MSD Mettre le Cap sur de Nouvelles Stratégies

JEUDI 25 MARS 2010

8:30	Auditorium	Amphithéâtre Callelongue
	Session Plénière	
10:30	Réservoirs du VIH & Primo-infection	
11:00	Pause - café sponsorisée par Gilead	
12:30	Sessions Parallèles Résistances du VIH	Sessions Parallèles Présentations Orales Libres (I)
14:00		Symposium Satellite de l'Industrie Tibotec Janssen-Cilag Changement de Traitement Antirétroviral chez les Patients en Succès Virologique : Quels Risques, Quels Bénéfices ?
15:30	Session Plénière Stratégies Antirétrovirales	
16:00	Pause - café sponsorisée par Gilead	
17:00	Conférence Plénière par Albert OSTERHAUS Le Défi Mondial des Maladies Émergentes	
18:30		Symposium Satellite de l'Industrie Abbot Virology Le VIH, une Pathologie Chronique : Quelles Priorités à prendre en charge ?

VENDREDI 26 MARS 2010

8:30	Auditorium	Amphithéâtre Callelongue
	Session Plénière	
10:30	Co-Infections	
11:00	Pause - café sponsorisée par Gilead	
12:30	Sessions Parallèles Patients VIH « Non Progressseurs »	Sessions Parallèles Présentations Orales Libres (II)
14:00	Sessions Parallèles Gestion à Long Terme de l'Infection à VIH (II) avec le Support de Bristol Myers Squibb	Sessions Parallèles Posters Discutés
15:00	Sessions Parallèles Mise au point d'un Vaccin contre le VIH	Sessions Parallèles « Post-CROI »
15:30	Pause - café sponsorisée par Gilead	
16:30	L'essentiel du Symposium	

9:20 ▶ 9:30

Welcoming Message / Message de Bienvenue

On Behalf of the Steering Committee / Au nom du Comité d'Organisation

Alain Lafeuillade, Toulon, France

9:30 ▶ 11:00

Plenary session / Session plénière

**EMERGING INFECTIOUS DISEASES /
MALADIES INFECTIEUSES EMERGENTES**

Auditorium

Chairpersons: Pierre Dellamonica (Nice, France), Gilles Hittinger (Toulon, France)

▶ 9:30

I-01 Hepatitis E: State-of-the-Art / Hépatite E : Etat des Lieux

Harry Dalton, Royal Cornwall Hospital & Virus Reference Department, London, UK

▶ 10:00

I-02 Lessons Learned from Chikungunya / Chikungunya : Leçons et Perspectives

Giovanni Rezza, Istituto Superiore di Sanità, Rome, Italy

▶ 10:30

I-03 The Influenza Challenge / Le Défi Grippal

Tim Nguyen, World Health Organisation (WHO), Geneva

11:00 ▶ 11:30



**Coffee break sponsored by /
Pause café sponsorisée par**



GILEAD

11:30 ▶ 13:00

Parallel session / Sessions parallèles

**LONG-TERM HIV MANAGEMENT (I) /
GESTION A LONG TERME DE L'INFECTION A VIH (I)**

Auditorium

Chairpersons: Isabelle Poizot-Martin (Marseille, France), Hervé Tissot-Dupont (Marseille, France)

▶ 11:30

I-04 Ageing with HIV: Next Challenges / Vieillir avec le VIH : Défis à Venir

Martin Fisher, Brighton and Sussex University Hospital, NHS, Brighton, UK

▶ 12:00

I-05 Cardiovascular Disease and HIV / Risque Cardiovasculaire et VIH

Esteban Martinez, Hospital Clínic-DIBAPS, University of Barcelona, Barcelona, Spain

▶ 12:15

I-06 Ageing Metabolism and HIV / Vieillissement Métabolique et VIH

Jacqueline Capeau, INSERM, Paris, France

▶ 12:35

**I-07 Neurodegeneration in the HAART Era / Dégénérescence Neurologique à l'Epoque des
Trithérapies**

Bruce Brew, University of New South Wales, Sydney, Australia



Traduction simultanée FR/AN and AN/FR
Simultaneous translation FR/EN and EN/FR

**PHARMACOLOGY OF HIV /
VIH, SESSION PHARMACOLOGIQUE**

Amphitheater Callelongue / Amphithéâtre Callelongue

Chairpersons: Rodolfe Garraffo (Nice, France), Caroline Solas (Marseille, France)

► **11:30**

I-08 Diffusion of New Antiretroviral Drugs in CSF / Diffusion des Nouveaux anti-Rétroviraux dans le LCR
Francesca Aweeka, University of California San Francisco, San Francisco, USA

► **11:50**

I-09 Inhibitory Quotient in HIV Pharmacology / Le Quotient Inhibiteur en Pharmacologie VIH
Charles La Porte, Ottawa Health Research Institute, Ottawa, Canada

► **12:10**

I-10 Drug-Drug Interactions - It is not only CYP450's which Matter / Interactions Pharmacologiques en dehors du Cytochrome P450

David Back, University of Liverpool, Liverpool, UK

► **12:30**

I-11 Evidence-based TDM for Antiretroviral Drugs / Le Suivi Pharmacologique des ARV Fondé sur les Preuves

Caroline Solas, Hôpital de la Timone, Marseille, France

13:00 ► 14:00

**Industry Satellite Symposium /
Symposium Satellite de l'Industrie
SCHERING PLOUGH**



**SHAPPING THE FUTURE OF HIV-HCV CO-INFECTED PATIENTS /
MODELER L'AVENIR DES PATIENTS CO-INFECTES VIH-VHC**

Amphitheater Callelongue / Amphithéâtre Callelongue

Chairperson: Stanislas Pol (Paris, France)

► **13:00**

Characteristics and Care of HIV-HCV Coinfected Patients (Prospecth study 2009) / Profil et Prise en Charge des Patients Co-Infectés VIH-VHC en 2009 (Étude Prospecth 2009)

Patrice Cacoub, Service de Médecine Interne, CHU Pitié Salpêtrière, Paris, France

► **13:15**

Maximizing Chances of Cure for HIV-HCV Coinfected Patients / Optimiser les Chances de Guérison chez les Patients Co-infectés VIH-VHC

Stéphanie Dominguez, Service d'Immunologie Clinique, Hôpital Henri Mondor, Paris, France

► **13:30**

Protease Inhibitor: Efficacy and Mutations Management / Anti-Protéases : Efficacité et Gestion des Résistances

Christian Payan, Département de Microbiologie, CHU – Hôpital Morvan, Brest, France

► **13:45**

Protease Inhibitor: a Trial in HIV-HCV Coinfecetd Patients / Anti-Protéases : un Protocole chez les Patients Co-infectés VIH-VHC

Stanislas Pol, Unité d'Hépatologie, Hôpital Cochin, Paris, France

► **13:50**

Questions - Answers / Questions – Réponses

13:00 ▶ 14:00

Session COREVIH

Session in French only / Session en français uniquement

LE DEPISTAGE COMMUNAUTAIRE

Auditorium

Modérateurs : Isabelle Ravaux (Marseille, France), Chantal Vernay-Vaisse (Marseille, France)

▶ 13:00

Introduction sur le COREVIH

Isabelle Ravaux, PH en infectiologie, AP-HM, vice-présidente du Corevih Paca Ouest Corse

▶ 13:05

Introduction sur le Dépistage Rapide

Chantal Vernay-Vaisse, chef de service Prévention IST, Conseil Général des Bouches du Rhône

▶ 13:10

Dépistage Rapide Auprès des Gays : le projet ANRS «DRAG»

Bruno Spire, chercheur en sociologie, Inserm U 912, président de AIDES, Marseille, France

▶ 13:25

Aspects Sociaux du Dépistage ou Expériences Européennes

Jean-Yves Le Talec, chercheur en sociologie, Université de Toulouse - Le Mirail, Toulouse, France

▶ 13:40

Discussion avec la salle

corevih
paca-ouest et corse

14:00 ▶ 15:30

Plenary session / Session plénière

IMMUNOLOGY OF HIV / IMMUNOLOGIE DU VIH

Auditorium

Chairpersons: Giuseppe Tambussi (Milan, Italy), Jean-François Delfraissy (Paris, France)

▶ 14:00

I-12 Is there a Role for Cytokine-Immune Based Therapy in HIV Disease Therapy? / Les Traitements Immunologique avec des Cytokine ont-ils une Place dans le VIH ?

Guido Poli, Istituto San Raffaele, Milan, Italy

▶ 14:30

I-13 IL-2/IL-7 Therapies in HIV Infection. From CD4 Increases to Clinical Outcomes / Immunothérapie de l'infection par le VIH par IL-2 et IL-7

Yves Lévy, Hôpital Henri Mondor, Créteil, France

▶ 15:00

I-14 NK Cells and Immune Activation in HIV / Cellules NK et Activation Immune dans l'Infection à VIH

Martin R. Goodier, Imperial College London, London, UK

15:30 ▶ 16:00



**Coffee break sponsored by /
Pause café sponsorisée par**



GILEAD



Traduction simultanée FR/AN and AN/FR
Simultaneous translation FR/EN and EN/FR

16:00 ▶ 17:00

Keynote lecture / Conférence plénière

Auditorium

KL-1 25 Years after Discovering HIV as the Cause of AIDS: Prospects for a Vaccine / 25 Ans Après Avoir Découvert le VIH Comme Agent Causal du SIDA : Recherche d'un Vaccin

Robert Gallo, University of Maryland School of Medicine, Institute of Human Virology, Baltimore, USA

17:00 ▶ 18:30

Industry Satellite Symposium /
Symposium Satellite de l'Industrie

MSD

Symposium in French only / Symposium en français uniquement

**STEERING FOR NEW STRATEGIES /
METTRE LE CAP SUR DE NOUVELLES STRATÉGIES**

Amphitheater Callelongue / Amphithéâtre Callelongue

Chairpersons: Alain Lafeuillade (Toulon, France), Jacques Izopet (Toulouse, France)

▶ **Can we Expect more than Undetectable Viremia Today? / Peut-on Attendre Plus que l'Indétectabilité Virologique Aujourd'hui**

Constance Delaugerre, Service de Virologie, CHU Saint Louis, Paris, France

▶ **New Pharmacological Needs: Diffusion Outside the Blood Compartment? / Nouvelles Exigences Pharmacologiques : Diffusion Extra-Plasmatique ?**

Rodolphe Garraffo, Hôpital Pasteur, Nice, France

▶ **First Line HAART: a Decisive Choice for the Long-Term / Première Ligne de Traitement : un Choix Décisif pour le Long Terme**

Isabelle Poizot Martin, HIV-Clinical center, Hospital Sainte Marguerite, Marseille, France



8:30 ▶ 10:30

Plenary session / Session plénière

**HIV RESERVOIRS & PRIMARY INFECTION /
RESERVOIRS DU VIH ET PRIMO-INFECTION**

Auditorium

Chairpersons: Jacques Izopet (Toulouse, France), Alain Lefeuille (Toulon, France)

▶ 8:30

I-15 HIV Latency Explained to Clinicians / La Latence du VIH expliquée aux Cliniciens

Jose Alcamí, Instituto de Salud Carlos III, Madrid, Spain

▶ 9:00

I-16 Update on HIV Reservoirs / Actualités sur les Réservoirs du VIH

Sarah Palmer, Swedish Institute for Infectious Disease Control and Karolinska Institute, Stockholm, Sweden

▶ 9:30

I-17 Anti-HIV Latency Drugs / Traitements Anti-Latence

David Margolis, University of North Carolina, Chapel Hill, USA

▶ 10:00

I-18 Translational Research at Acute HIV Infection / Recherche Translationnelle au Stade de Primo-infection

Jean-Pierre Routy, McGill University, Montreal, Canada

10:30 ▶ 11:00



**Coffee break sponsored by /
Pause café sponsorisée par**



GILEAD

11:00 ▶ 12:30

Parallel sessions / Sessions parallèles

HIV RESISTANCE / RESISTANCE DU VIH

Auditorium

Chairpersons: Catherine Tamalet (Marseille, France), Jean-Claude Tardy (Lyon, France)

▶ 11:00

I-19 Use of New Technologies to Detect and Understand HIV Drug Resistance / Utilisation de Nouvelles Technologies pour Détecter et Comprendre les Résistances du VIH

Michael Kozal, Yale University, New Haven, USA

▶ 11:30

I-20 Resistance to New Antiretrovirals (ETV, Anti-Integrases, Entry Inhibitors) / Résistance aux Nouveaux Anti-rétroviraux (Etravirine, anti-Intégrase, anti-CCR5)

Francesca Ceccherini-Silberstein, University of Rome Tor Vergata, Rome, Italy

▶ 12:00

I-21 Use of New Drug Resistance Markers to Predict Virologic Response to Antiretrovirals / Utilisation de Nouveaux Marqueurs de Résistance pour Prédire la Réponse Virologique aux Anti-rétroviraux

Mark Wainberg, McGill University, Montreal, Canada



Traduction simultanée FR/AN and AN/FR
Simultaneous translation FR/EN and EN/FR

11:00 ► 12:30

FREE ORAL PRESENTATIONS I / PRESENTATIONS ORALES LIBRES I

Amphitheater Callelongue / Amphithéâtre Callelongue

Chairpersons: Patricia Enel (Marseille, France), Philippe Halfon (Marseille, France)

* indicates the presenting author / * indique le présentateur

► 11:00

0-01 Evolution of Tuberculosis/HIV Co-Infection in California During the Haart Era, 1996-2007

John Metcalfe (1)* Matt Facer (2) Mark Damesyn (2) Qiang Xia (2) James Watt (3) Julia Hill (3) Philip Hopewell (1) Janice Westenhouse (3) Jennifer Flood (3)

(1) UCSF, San Francisco, USA (2) Office of AIDS, California Department of Public Health, San Francisco, USA (3) TB Control Unit, California Department of Public Health, Richmond, USA

0-02 CANCELLED

► 11:10

0-03 Screening of Differentially Expression Gene in HIV/HCV Coinfection Patients.

zhengrong Yang (1)* Jing Zhao (1) Lin Chen (1)

(1) Shenzhen Center for Disease Control and Prevention, Shenzhen, China

11:20

0-04 Nk-pDC Cross-Talk Leads to the Generation of Mtrail+Ifn-A+Cytotoxic pDC s Following HIV-1 Infection of pDC s. Consequences on the Control of Viral Replication

Héla Saïdi (1) Marlene Bras (1)* Formaglio Pauline (1) Melki Marie-thérèse (1) Gougeon Marie-Lise (1)

(1) Institut Pasteur, Paris, France

► 11:30

0-05 Th1/Th17 Gammadelta T Cells Are Expanded in HIV-1 Infected Patients and Respond to Candida Albicans.

Alessandro Poggi (1)* Daniela Fenoglio (2) Florinda Battaglia (2) Silvia Catellani (3) Alessandra Musso (1, 6) Maurizio Setti (4) Giuseppe Murdaca (5) Maria Raffaella Zocchi (6)

(1) National Institute for Cancer Research, Genoa, Italy (2) CEBR, University of Genoa, Genoa, Italy (3) Department of Oncohematology, University of Genoa, Genoa, Italy (4) Department of Internal Medicine, University of Genoa, Genoa, Italy (5) Department of Semiotics, University of Genoa, Genoa, Italy (6) Scientific Institute San Raffaele, Department of Immunology, Milan, Italy

► 11:40

0-06 NK-Dependent Survival of HIV-1 Infected DCs. Pivotal Role of HMGB1.

Marie-Thérèse Melki (1)* Héla Saïdi (1) Marie-Lise Gougeon (1)

(1) Institut Pasteur, Paris, France

► 11:50

0-07 $\gamma\delta$ T Cells are ADCC Effectors in Elite HIV Controllers

Bhawna Poonia (1) David Riedel (1) Cristiana Cairo (1) Mohammed Sajadi (1) Cheryl Armstrong (1) David Pauza (1)*

(1) Institute of Human Virology, University of Maryland Medical School, Baltimore, USA

► 12:00

0-08 CpG Methylation Controls Reactivation of HIV from Latency

Jana Blazkova (1, 2, 3)* Katerina Trejbalova (1, 2) Francoise Gondois-Rey (1) Halfon Philippe (4) Philibert Patrick (5) Eric Verdin (6) Daniel Olive (1) Carine van Lint (3) Jiri Hejnar (2) Ivan Hirsch (1)

(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, and Université Méditerranée, Marseille, France (2) Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic (3) Laboratory of Molecular Virology, Institute for Molecular Biology and Medicine (IBMM) University of Brussels (ULB), Gosselies, Belgium (4) Department of Virology, Alphabio Laboratory, Marseille, France (5) Department of Infectious Diseases, Hôpital Ambroise Paré, Marseille, France (6) Gladstone Institute of Virology and Immunology, San Francisco, USA

 12:30 ▶ 14:00

Industry Satellite Symposium /
Symposium Satellite de l'Industrie
TIBOTEC JANSSEN CILAG

Symposium in English only / Symposium en anglais uniquement

SWITCHING FROM STABLE REGIMEN: WHICH RISKS, WHICH BENEFITS? /
CHANGEMENT DE TRAITEMENT ANTIRÉTROVIRAL CHEZ LES PATIENTS
EN SUCCÈS VIROLOGIQUE : QUELS RISQUES, QUELS BÉNÉFICES ?

Amphitheater Callelongue / Amphithéâtre Callelongue

Chairpersons: Isabelle Poizot-Martin (Hôpital Sainte Marguerite, Marseille, France), Jose Arribas (Hospital La Paz, Madrid, Spain)

▶ **NNRTI regimen: Capitalizing on the class? / Associations avec un INNTI : changer en capitalisant sur la classe ?**

Mark Nelson, Chelsea and Westminster Hospital, London, UK

▶ **PI/r regimen: Without compromising the high genetic barrier? / Associations avec IP/r : changer sans compromettre la barrière génétique à la résistance ?**

Gianni di Perri, Department of Infectious Diseases, University of Torino, Torino, Italy

▶ **From 3 to 1: Is monotherapy a valid option for simplification? / De 3 vers 1 : la monothérapie est elle une option ?**

Christine Katlama, Service de Maladies Infectieuses et Tropicales, CHU Pitié Salpêtrière, Paris, France

14:00 ▶ 15:30

Plenary session / Session plénière

ANTIRETROVIRAL STRATEGIES / STRATEGIES ANTIRETROVIRALES

Auditorium

Chairpersons: Hans J Stellbrink (Hamburg, Germany), Alain Rieu (Toulon, France)

▶ **14:00**

ARV Strategies in 2010: What's New? / Stratégies de Traitement : Quoi de Neuf en 2010 ?

Jose Gatell, University of Barcelona, Barcelona, Spain

▶ **14:30**

ARV Therapy in Special Populations / Traitement Antirétroviral dans des Populations Particulières

Stéfano Vella, Istituto Superiore di Sanità, Rome, Italy

▶ **15:00**

Novel Targets, Novel Strategies / Nouvelles Cibles, Nouvelles Stratégies

Robert Redfield, Institute of Human Virology, Baltimore, USA

15:30 ▶ 16:00



Coffee break sponsored by /
Pause café sponsorisée par



GILEAD



16:00 ▶ 17:00

Keynote lecture / Conférence plénière

Auditorium

The Global Challenge of Emerging Infectious Diseases / Le Défi Mondial des Maladies Emergentes

Albert Osterhaus, Head Department of Virology, Erasmus MC, Rotterdam, The Netherlands

17:00 ▶ 18:30

Industry Satellite Symposium /
Symposium Satellite de l'Industrie

ABBOTT

**HIV, A CHRONIC DISEASE: WHAT PRIORITIES TO MANAGE? /
LE VIH, UNE PATHOLOGIE CHRONIQUE : QUELLES PRIORITÉS
À PRENDRE EN CHARGE ?**

Amphitheater Callelongue / Amphithéâtre Callelongue

Chairpersons: Alain Lafeuillade (Toulon, France), Christine Katlama (Paris, France)

▶ **HIV, Antiretrovirals and Central Nervous System / VIH, Antirétroviraux et Système Nerveux Central**

Scott Letendre, Division of Infectious Diseases, University of California San Diego, San Diego, USA

▶ **Management of Metabolic Disorders / La Gestion des Troubles Métaboliques**

Jean-Luc Meynard, Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France

▶ **HIV Eradication, An Achievable Goal? / L'éradication, Un Objectif Atteignable ?**

Jean-Claude Tardy, Hôpital de la Croix Rousse, Lyon, France



8:30 ▶ 10:30

Plenary session / Session plénière

CO INFECTIONS / CO-INFECTIONS

Auditorium

Chairpersons: Marc Bourlière (Marseille, France), Isabelle Ravaux (Marseille, France)

▶ 8:30

I-22 HIV / HPV Coinfection: State-of-the-Art / Co-infection VIH et HPV : Actualités

Franco Buonaguro, Laboratory of Molecular Biology and Viral Oncogenesis & AIDS Reference Center, Naples, Italy

▶ 9:00

I-23 Hepatitis B: Treatment Strategies and Resistance / Hépatite B : Stratégies Thérapeutiques et Résistance

Vicente Soriano, Hospital Carlos III, Madrid, Spain

▶ 9:30

I-24 New anti-HCV Drugs in the Pipeline / Les Nouvelles Molécules anti-VHC

Marc Bourlière, Fondation Saint Joseph, Marseille, France

▶ 10:00

I-25 Liver Transplantation in Co-infected Patients / Transplantation Hépatique chez les Patients Co-infectés

Jose M Miró, Hospital Clínic, Barcelona, Spain



BEST POSTER AWARD / REMISE PRIX POSTER

Courtesy of / Courtoisie de ViiVhealthcare

10:30 ▶ 11:00



**Coffee break sponsored by /
Pause café sponsorisée par**



GILEAD

11:00 ▶ 12:30

Parallel sessions / Sessions parallèles

HIV CONTROLLERS / PATIENTS VIH « NON PROGRESSEURS »

Auditorium

Chairpersons: Antoine Cheret (Toulon, France), Olivier Lambotte (Le Kremlin-Bicêtre, France)

▶ 11:00

I-26 HIV Controllers: State-of-the-Art / Non Progresseurs : Etat des Lieux

Olivier Lambotte, INSERM U802, Université Paris-Sud, Le Kremlin-Bicêtre, France

▶ 11:30

I-27 The Role of Cytotoxic T Cells / Rôle des Cellules T Cytotoxiques

Asier Sáez-Cirión, Unité de Régulation des Infections Rétrovirales, Institut Pasteur, Paris, France

▶ 11:50

I-28 Potential Inflammatory Consequences in HIV Controllers / Conséquences Possibles de l'Inflammation chez les Non Progresseurs

Peter Hunt, Positive Health Program, San Francisco General Hospital, San Francisco, USA

▶ 12:10

The Role of Host Genetic Determinants / Rôle des Facteurs Génétiques

Paul de Bakker, Brigham and Women's Hospital, Harvard Medical School-Partners Healthcare Systems Center for Genetics and Genomics, Boston, USA



Traduction simultanée FR/AN and AN/FR
Simultaneous translation FR/EN and EN/FR

11:00 ▶ 12:30**FREE ORAL PRESENTATIONS II / PRESENTATIONS ORALES LIBRES II****Amphitheater Callelongue / Amphithéâtre Callelongue**

Chairpersons: Eric Jullian (Toulon, France), Patrick Phillibert (Marseille, France)

* indicates the presenting author / * indique le présentateur

▶ 11:00**O-09 Morbidity Associated with Hepatitis E Virus Infection in Endemic Setting.**

Michael Favorov (1)* Makhmud Sharapov (2)

(1) International Vaccine Institute, Seoul, Korea, Republic of (2) Tashkent Pediatric Medical Institute and Central Asia Epidemiology Network, Ministry of Health, Tashkent, Uzbekistan

▶ 11:10**O-10 Hepatic Cytolysis and Hepatitis E Virus Infection in HIV-Positive Patients.**

Marie-Christine Mazon (1) Elisabeth Nicand (2) Sophie Tesse (2) Esma Badsì (3) Jean-Dominique Magnier (3) Marie-José Sanson Le Pors (1) Jean-François Bergmann (3) Pierre Sellier (3)*

(1) Hôpital Lariboisière, Service de bactériologie-Virologie, Paris, France (2) Hôpital d'Instruction des Armées du Val de Grace, CNR virus de l'hépatite E, Paris, France (3) Hôpital Lariboisière, service de Médecine Interne, Paris, France

▶ 11:20**O-11 Co-Receptor Usage Prediction at Quasispecies Level Using Ultra-Deep Pyrosequencing on both Circulating and Proviral HIV in Patients Candidates to CCR5 Antagonist Treatment**

Isabella Abbate (1)* Gabriella Rozera (1) Chiara Tommasi (1) Alessandro Bruselles (1) Barbara Bartolini (1) Emanuele Nicastrì (1) Pasquale Narciso (1) Maria R. Capobianchi (1)

(1) INMI L.Spallanzani, Rome, Italy

▶ 11:30**O-12 Semen May Harbor HIV Despite Effective HAART : Another Piece in the Puzzle**

Philippe Halfon (1)* Claude Giorgetti (2) Hacène Khiri (1) Guillaume Pénaranda (1)* Terriou (2) G Porcu-Buisson (2) Véronique Chabert-Orsini (2)

(1) Laboratoire Alphabio, Marseille, France (2) Institut Médical de Reproduction, Marseille, France

▶ 11:40**O-13 Tenofovir (TDF) Containing First-Line HAART is Associated with Changes in Plasma Parameters Suggestive of Increased Bone Resorption**

Pablo Labarga (1)* Pablo Barreiro (1) Carlos A. Sanchez (1) Jose Medrano (1) Eugenia Vispo (1) Jose Vicente Fernandez (1) Francisco Blanco (1) Juan Gonzalez-Lahoz (1) Vicente Soriano (1)

(1) Hospital Carlos III, Madrid, Spain

▶ 11:50**O-14 Side Effects Associated with Use of Nevirapine in HIV Treatment Naïve Patients with Respect to Baseline CD4 Count**

Manoj Shevkani (1)* Bankim Mankad (1) Goral Rathod (1) Bipin Amin (1) Asha Shah (1) Umesh Nihalani (1) Hemang Purohit (1) Burzin Kavina (1) Urvi Derasari (1) Sanjeev Prajapati (1)

(1) ART center B J Medical College, Ahmedabad, India

▶ 12:00**O-15 The Monet Trial: Correlation Between Hepatitis C Coinfection and HIV RNA Responses During Darunavir/Ritonavir Monotherapy, for Patients With HIV RNA <50 Copies/mL at Baseline.**

Jose Arribas (1)* Maria Luisa Montes (1) Andrew Hill (2) Manyu Prakash (2) Christiane Moecklinghoff (2) MONET Study Group (3)

(1) Hospital la Paz, Madrid, Spain (2) Tibotec, Mechelen, Belgium (3) MONET Study Group, Europe, Spain

▶ 12:10**O-16 Inhibitors of Human Immunodeficiency Virus-1 Replication Targeting the Human Dead-Box Polypeptide 3 (DDX3) RNA Helicase**

Giovanni Maga (1)* Federico Falchi (2) Anna Garbelli (1) Marco Radi (2) Stefania Paolucci (3) Fausto Baldanti (3) Maurizio Botta (2)

(1) Institute of Molecular Genetics IGM-CNR, Pavia, Italy (2) Dept. of Technical Pharmacology, University of Siena, Siena, Italy (3) Virology Unit, University Hospital IRCCS S.Matteo, Pavia, Italy

12:30 ▶ 14:00

Parallel sessions / Sessions parallèles

**LONG-TERM HIV MANAGEMENT (II) /
GESTION A LONG TERME DE L'INFECTION A VIH (II)**



Bristol-Myers Squibb
Prolonger et embellir la vie

Auditorium

Chairpersons: Isabelle Poizot Martin (Marseille, France), Pierre Cau (Marseille, France)

With the support of Bristol-Myers Squibb / avec le soutien de Bristol-Myers Squibb

▶ 12:30

I-29 Progeria: a model for HIV? / La Progéria : un Modèle pour le VIH ?

Pierre Cau, Université de la Méditerranée Aix-Marseille II, Marseille, France

▶ 12:50

I-30 Accelerated Immune Senescence in HIV / Vieillesse Immunologique Accélérée dans l'Infection VIH

Victor Appay, Hôpital Pitié-Salpêtrière, Paris, France

▶ 13:10

I-31 Bone Aging and HIV / Vieillesse Osseux et VIH

Patrick Mallon, University College Dublin, Dublin, Ireland

▶ 13:20

Sexual Dysfunction: HIV, HAART or premature aging? / Troubles Sexuels : VIH, traitement, ou vieillissement accéléré ?

Giovanni Guaraldi, University of Modena and Reggio Emilia, Modena, Italy

12:30 ▶ 14:00

DISCUSSED POSTERS / COMMUNICATIONS AFFICHEES DISCUTEES

Amphitheater Callelongue / Amphithéâtre Callelongue

Chairpersons: Mark Wainberg (Montreal, Canada), Jade Ghosn (Paris, France), Antoine Cheret (Toulon, France)

* indicates the presenting author / * indique le présentateur

▶ 12:30

P-001 HIV/AIDS Infection in Ukraine: A Review of Epidemiological Data

Dr. Larissa Burruano (1)*

(1) CompNet, Clinic for Dermatology and Allergology, Ruhr-University, Bochum, Germany

▶ 12:35

P-002 Human Papillomavirus(HPV) Genotypes Among HIV-Infected and HIV-Uninfected Women in Mozambique

Massimo Magnano San Lio (1, 2)* Ivo Marchetti (3) Carla Carrilho (4) Maria Pia Cioni (3) Giovanni Guidotti (3, 1) Cristina Moscatelli (3, 1) Fabio Taponeco (6) Elias Suizane F. Walle (5) Ines Zimba (7) Generoso Bevilacqua (3)

(1) Community of Sant'Egidio, Drug Resources Enhancement against AIDS and Malnutrition (DREAM) Program, Roma, Italy (2) Azienda U.S.L. Roma F, Civitavecchia, Italy (3) Division of Surgical, Molecular and Ultrastructural Pathology, University of Pisa and University Hospital of Pisa, Pisa, Italy (4) Department of Pathology, Universidade Eduardo Mondlane, Hospital Central de Maputo, Ministério de Saúde, Maputo, Mozambique (5) Department of Gynecology, Hospital Central de Maputo, Ministério de Saúde, Maputo, Mozambique (6) Department of Gynecology, University Hospital of Pisa, Pisa, Italy (7) DREAM Health Center of Benfica, Maputo, Mozambique

▶ 12:40

P-003 Factors Affecting Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome Preventive Behavior among Pregnant Women in ANC Clinic in Maternity Hospital, Nepal

Sumi Amatya (1)*

(1) London School of Hygiene and Tropical Medicine, London, UK



Traduction simultanée FR/AN and AN/FR
Simultaneous translation FR/EN and EN/FR

► 12:45

P-004 Treatment of Highly Pathogenic Filovirus Infections using Advanced Antisense Technology

Travis Warren (1)* Kelly Warfield (1, 3) Jay Wells (1) Dana Swenson (1, 3) Candace Lovejoy (2, 4) Patrick Iversen (2) Sina Bavari (1)

(1) USAMRIID, Ft. Detrick, Maryland, USA (2) AVI BioPharma, Inc., Corvallis, Oregon, USA (3) Integrated BioTherapeutics, Inc., Germantown, Maryland, USA (4) Siga Technologies, Inc., Corvallis, Oregon, USA

► 12:50

P-005 The HIV-1 Viral Protein TAT Modulates Glutamate and GABA Exocytosis from Human and Mouse Neocortical Nerve Endings by Acting at Different Binding Sites

Maria Summa (1) Paolo Severi (1) Aldamaria Puliti (1) Maurizio Raiteri (1) Anna Pittaluga (1)*

(1) DIMES, Genova, Italy

► 12:55

P-006 A Role for the Tetraspanin CD81 on the Late Steps of HIV-1 Replication in T-Lymphoblastic Cells

Delphine Muriaux (1)*

(1) Inserm U758, LYON, France

► 13:00

P-007 Hijacking Of PI3K/AKT Signaling Pathway by Hepatitis C Virus in TLR9-Activated Human Plasmacytoid Dendritic Cells

Jonathan Florentin (1)* Clélia Dental (1) Guylène Firaguay (1) Françoise Gondois-Rey (1) Vassili Soumelis (2) Thomas F. Baumert (3) Jacques A. Nunès (1) Daniel Olive (1) Ivan Hirsch (1)

(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, and Université Méditerranée, Marseille, France (2) Institut Curie, Paris, France (3) INSERM UMR_S748, Université de Strasbourg, Strasbourg, France

► 13:05

P-008 Multicolor Flow Cytometry Analysis of Innate Responses Following in Vitro Interaction of PBMC with Hepatitis C Virus

Françoise Gondois-Rey (1)* Diana Herrera (1) Daniel Olive (1) Ivan Hirsch (1)

(1) INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, and Université Méditerranée, Marseille, France

► 13:10

P-009 Comparison Of Cytotoxic Activity and Interferon-G Secretion by Natural Killer Cells in HIV-1 and HIV-2 Infected Individuals.

Samuel Victor Nuvor (1)* Sarah Rowland-jones (2) Hilton Whittle (3) Assan Jaye (3)

(1) University of Cape Coast, Cape Coast, Ghana (2) wetherall Institute of Molecular Medicine, Oxford, UK (3) Medical Research Council, Banjul, Gambia

► 13:15

P-010 Late HIV Infection Modulates the Expression and Activity of Cathepsin B, and its Inhibitors in Macrophages: Implications in Neuropathogenesis.

Eillen Rodriguez (1)* Marines Plaud (1) Rafael Romeu (2) Richard Skolasky (3) Loyda Melendez (1)

(1) University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico (2) University of Puerto Rico: Main Campus, San Juan, Puerto Rico (3) John Jopkins University, Baltimore, Maryland, USA

► 13:20

P-011 Impact of Short Term HAART Initiated during the Acute or Chronic Stage on SIV Infection of the Male Genital Tract

Marina Moreau (1)* Anna Le Tortorec (1) Hélène Denis (1) Claire Deleage (1) Anne-Pascale Satie (1) Olivier Bourry (1) Pierre Roques (2) Bernard Jégou (1) Roger Le Grand (2) Nathalie Dejuçq-Rainsford (1)

(1) Inserm U625 GERHM, Rennes, France (2) Service d'immuno-virologie, CEA, Fontenay-aux-roses, France

► 13:25

P-012 Enhanced Induction of HIV-Specific CTL by Dendritic Cell-Targeted Delivery of SOCS-1 siRNA

Sandesh Subramanya (1, 2)* Chunting Ye (1, 2) Sang-Soo Kim (1, 2) Premalata Shankar (1, 2)

(1) TTUHSC, El Paso, USA (2) Harvard Medical School, Boston, USA



► **13:30**

P-013 Effect of Antiretroviral Therapy (ART) on HIV-1 & 2 (Subtype C) Infection and its Relationships to Cognitive Function and Quality of Life.

Gopukumar Kumarpillai (1)* Shobini L. Rao (1, 2) Prabha S.Chandra (1, 2) Satishchandra* (1, 2) Mahendra Kumar (1, 2, 3)

(1) University of Calgary, Calgary, Canada (2) NIMHANS, Bangalore, India (3) Miami School of Medicine, Florida, USA

P-014 CANCELLED

► **13:35**

P-015 Effect of Range of Spread of CD4 Count and RNA Level on the Efficacy of HIV Treatments

George Towfic (1)* Samira Kettoola (1)

(1) Clarke College, Dubuque, USA

► **13:40**

P-016 HIV Infection in Elderly Patients Aged more than 65 Years

Farahnaz Almasi (1)*

(1) Paris 6 University, Paris, France

14:00 ► 15:00

Parallel sessions / Sessions parallèles

TOWARDS AN HIV VACCINE / MISE AU POINT D'UN VACCIN CONTRE LE VIH

Auditorium

Chairpersons: Alain Lafeuillade (Toulon, France), Pierre Pellegrino (London, UK)

► **14:00**

Mucosal Immunity : a New Pathway for HIV Vaccine Development / L'Immunité Muqueuse : une Nouvelle Voie pour la Mise au Point de Vaccins

Marc Girard, Académie Nationale de Médecine, Lyon, France

► **14:15**

I-32 Recent Insights from Basic Science / Données Récentes des Sciences Fondamentales

Patrice Debré, INSERM U945, C.E.R.V.I., Paris, France

► **14:30**

I-33 Progress Towards Development of an HIV Vaccine: A Report from the AIDS Vaccine Conference / Progrès vers la Mise au Point d'un Vaccin anti-VIH

Luigi Buonaguro, Molecular Biology and Viral Oncogenesis Unit & AIDS Reference Center, Istituto Nazionale Tumori «Fond. G. Pascale», Naples, Italy

► **14:45**

What Can we Expect? / Que Peut-on Attendre ?

Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland



14:00 ▶ 15:00**POST CROI SESSION / SESSION « POST-CROI »****Amphitheater Callelongue / Amphithéâtre Callelongue**

Chairpersons: Gérard Lepeu (Avignon, France), Jade Ghosn (Paris, France)

This session is dedicated to sum up the recent data presented at the 17th Conference on Retroviruses and Opportunistic Infection (CROI) held in San Francisco, USA on February 16-20, 2010.
/ Cette session a pour but de résumer les faits marquants de la dernière CROI organisée à San Francisco, USA, du 16 au 20 Février 2010.

▶ 14:00**in Epidemiology / en Epidémiologie**

Sabine Yerly, Hôpitaux Universitaires de Genève, Geneva, Switzerland

▶ 14:15**in Virology / en Virologie**

Leondios Kostrikis, University of Cyprus, Nicosia, Cyprus

▶ 14:30**in Immunology / en Immunologie**

Marie-Lise Gougeon, Institut Pasteur, Paris, France

▶ 14:45**in Therapy / en Thérapeutique**

Jade Ghosn, CHU Bicêtre, Paris, France

15:00 ▶ 15:30**Coffee break sponsored by /
Pause café sponsorisée par****GILEAD****15:30 ▶ 16:30****Reporter Session / L'Essentiel du Symposium****Auditorium**

Chairpersons: Catherine Tamalet (Marseille, France), Alain Lefeuille (Toulon, France)

▶ 15:30**Virological Aspects / Aspects Virologiques**

Jean-Claude Tardy, Hôpital de la Croix Rousse, Lyon, France

▶ 15:45**Immunological Aspects / Aspects Immunologiques**

Guido Poli, Istituto San Raffaele, Milan, Italy

▶ 16:00**Clinical Aspects of HIV & Other Infections / Aspects Cliniques**

Hans J Stellbrink, Infektionsmedizinisches Centrum Hamburg ICH, Hamburg, Germany

▶ 16:15**Therapeutic Aspects of HIV & Other Infections / Aspects Thérapeutiques**

Mark Nelson, Chelsea and Westminster Hospital, London, UK

POSTERS COMMUNICATIONS AFFICHÉES

Goudes Room / Salle Les Goudes


Posters are located in the Goudes room, level 2.

The best poster will be awarded on Friday, March 26 at 10:30 at the end of the plenary session in the Auditorium.

Les communications affichées sont situées dans la salle Les Goudes, niveau 2.

Le prix du meilleur poster sera remis le vendredi 26 mars à 10h30 à la fin de la plénière dans l'Auditorium.

POSTERS MAP / PLAN DES COMMUNICATIONS AFFICHÉES



Discuted posters

P001 - P016

A: Basic Sciences

A1: HIV, Virology

P017 - P021

A2: HIV, Immunology

P022 - P027

A3: Hepatitis, Virology

P028 - P029

A4: Hepatitis, Immunology

P030 - P031

B: Clinical Sciences

B1: HIV, Clinical Manifestations

P033 - P041

B2: HIV, Therapy

P042 - P061

B3: HIV, Side Effects

P062 - P069

B4: HIV, Tumors

P070 - P071

B5: HIV, Others

P072 - P082

B6: Hepatitis, Therapy

P083 - P084

Total B7: Hepatitis, Other

P085 - P087

B8: STDs

P088

B9: Other, Clinical Science

P090 - P094

C: Epidemiology & Prevention

C1: HIV, Epidemiology & Prevention

P095 - P149

C2: Hepatitis, Epidemiology & Prevention

P150 - P154

C3: Other, Epidemiology & Prevention

P155 - P162

D: Pharmacology

D1: HIV, New Drugs

P163 - P166

D3: Therapeutic Drug Monitoring

P167

E: Emerging Infectious Diseases

E1: Laboratory Aspects

P168 - P175

E2: Clinical Aspects

P176 - P180

E4: Other, Emerging Infectious Diseases

P181 - P192

* indicates the presenting author /* indique le présentateur

A Basic Science

► A1: HIV, Virology

P-017 Pro 2000, a Broadly Active Anti-HIV Sulfonated Compound, Inhibits Viral Entry by Multiple Mechanisms.

Dana Huskens (1) Albert T Profy (2) Kurt Vermeire (1) Dominique Schols (1)*

(1) Rega Institute for Medical Research, Leuven, Belgium (2) Indevus Pharmaceuticals, Lexington, USA

P-018 Potential Role of HIV-1 NEF and Human M6B in HIV-Associated Neurological Disorders

Jessica Moetter (1)* Silke Hoffmann (1) Esther Jonas (2) Dieter Willbold (1, 2)

(1) Forschungszentrum Juelich, ISB-3, Structural Biochemistry, Juelich, Germany (2) Heinrich-Heine-Universität Duesseldorf, Institut fuer Physikalische Biologie, Duesseldorf, Germany

P-019 CANCELLED

P-020 HIV-1 Evolution and Drug Resistance among Patients Receiving Antiretroviral Therapy in San Mateo County, California, 1997-2006.

Sudeb Dalai (1)* Jonathan Dyal (1) Keyan Salari (1) Seble Kassaye (1) Vivian Levy (2) Dennis Israelski (2) David Katzenstein (1)

(1) Stanford University School of Medicine, Stanford, USA (2) San Mateo Medical Center, San Mateo, USA

P-021 Length Variation in HIV-1 GP120 as the Product of DNA Misalignment Mechanism

Silvia Guglietta (1) Giuseppe Pantaleo (1) Cecilia Graziosi (1)*

(1) CHUV, Lausanne, Switzerland

► A2: HIV, Immunology

P-022 Nucleolin Relocalization Associated with Pre-Lethal Alterations of T Cell Morphology: Redefining Cell Death in HIV Infection.

Giuseppa Visalli (1) Maria Paola Bertuccio (1) Cristina Chirico (1) Giovanni Pellicanò (3) Pasquale Spataro (1) Riccardo Ientile (4) Isa Picerno (1) Giuseppe Piedimonte (2)*

(1) Department of Hygiene and Public Health University of Messina, Messina, Italy (2) Department of Biomorphology and Biotechnology University of Messina, Messina, Italy (3) Department of Human Pathology University of Messina, Messina, Italy (4) Department of Biochemistry University of Messina, Messina, Italy

P-023 The Immunoglobulin Constant Region Modulates Antigen Binding Affinity and Functional Activities of the Broadly Neutralizing 2F5 HIV Specific Antibody

Daniela Tudor (1)* Anne-Sophie Drillet (1) Isabelle Schwartz-Cornil (2) Ruizhong Shen (3) Phillip D. Smith (3) Morgane Bomsel (1)

(1) Institut Cochin, Paris, France (2) INRA, Jouy-en-Josas, France (3) University of Birmingham, Alabama, USA

P-024 Definition of the Interacting Interfaces of Apobec3G and HIV-1 Vif using Mappit Mutagenesis Analysis

Delphine Lavens (1, 2)* Frank Peelman (1, 2) José Van der Heyden (1, 2) Isabel Uyttendaele (1, 2) Dominiek Catteeuw (1, 2) Bertrand Van Schouwbroeck (3) Julia Kurth (3) Sabine Hallenberger (3) Reginald Clayton (3) Jan Tavernier (1, 2)

(1) University of Ghent, Ghent, Belgium (2) VIB, Ghent, Belgium (3) TIBOTEC, Mechelen, Belgium

P-025 Expansion of Vdelta1 T Lymphocytes Reactive to *C. Albicans* in HIV-1 Infected Patients: Effect of Influenza Virus Vaccine.

Maria Raffaella Zocchi (1)* Daniela Fenoglio (2) Alessia Parodi (2) Alessandra Ferrera (2) Paolo Durando (3) Roberto Gasperini (3) Silvia Catellani (4) Alessandro Poggi (5)

(1) Scientific Institute San Raffaele, Department of Immunology, Milan, Italy (2) CEBR, University of Genoa, Genoa, Italy (3) Department of Health Science, San Martino Hospital, Genoa, Italy (4) Department of Oncohematology, University of Genoa, Genoa, Italy (5) National Institute for Cancer Research, Unit of Molecular Oncology and Angiogenesis, Genoa, Italy

P-026 HIV-Patients Discrimination According to Phenotype and Functional Assay of T-Cells Subsets.

Marie-Paule Guillaume (1)* Rafik Karmali (1) Francis Corazza (1) Jean Duchateau (1)

(1) CHU-Brugmann, Bruxelles, Belgium

P-027 Evaluation of Adult Immunological Outcomes from Kimironko Health Center Art Program, 2007 to 2008.

Andre Mbayiha H. (1)*

(1) AIDS Healthcare Foundation, Kigali, Rwanda

► **A3: Hepatitis, Virology**

P-028 Implications of HCV Natural Genetic Diversity on HCV NS5B Inhibitor NM283

Victoria L Demetriou (1)* Leondios G Kostrikis (1)

(1) University of Cyprus, Nicosia, Cyprus

P-029 Viral Variability Study in Follow-Up Sera from HIV-HBV-HCV Coinfected Patients

Stefania Taffon (1) Domenico Genovese (1, 2) Stefano Dettori (1) Paola Chionne (1) Claudio Argentini (1, 2) Maria Blasi (1) Stefania Catone (1, 2) Nicoletta Marino (3) Francesco Mazzotta (3) Maria Rapicetta (1)*

(1) Istituto Superiore di Sanita', Dept. MIPI, Viral Hepatitis Uni, Rome, Italy (2) Istituto Superiore di Sanita', Dept. FARM, Rome, Italy (3) Santa Maria Annunziata Hospital, Infectious Diseases Department, Florence, Italy

► **A4: Hepatitis, Immunology**

P-030 Pilot Trial of Oral Therapeutic HIV Vaccine, V-1 Immunitor, on HIV and HIV/HCV Patients in Russia

aldar bourinbaier (1)* vladimir orlovsky (1) vichai jirathitikal (1) orapun metadilogkul (1) popov dmitry (1, 1)

(1) immunitor USA Inc, college park, USA

P-031 Evaluation of Immune Response Profiles of Individuals With Chronic Hepatitis C Treated with Interferon Alpha and Ribavirin, in the Foundation of Tropical Medicine of Amazonas.

Ana Ruth Araújo (2) Liziara Silva Fraporti (1, 3) Kátia Luz Torres (1) João Paulo Diniz Pimentel (1) Tatiane Amabile (1) Andrea Tarragô (1) Laura Patrícia Viana Maia (1, 3) Nadja Garcia (1, 3) Walter Luiz Neves (1) Adriana Malheiro (1, 3)*

(1) Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil (2) Fundação de Medicina Tropical do Amazonas, Manaus, Brazil (3) Universidade do Amazonas, Manaus, Brazil

► **A5: Others, Basic Science**

P-032 CANCELLED



B Clinical Science

► B1: HIV, Clinical Manifestations

P-033 HIV-Related Morbidity Rate, Thirteen Years after the Introduction of Highly Active Antiretroviral Therapy (1996-2009)

Roberto Manfredi (1)*

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-034 The «AIDS Presenters» Phenomenon, Thirteen Years after the Availability of Potent, Combination Antiretroviral Therapy

Roberto Manfredi (1)*

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-035 The Prevalence and Presentation of Heart Disease in HIV Positive Adults Attending a Clinic at Mulago Hospital, Kampala, Uganda

Andrew Ocero (1, 2)* Elly Katabira (2) Roy Mugerwa (2)

(1) *Northern Uganda Malaria AIDS and Tuberculosis Programme, Gulu, Uganda* (2) *Makerere University, Kampala, Uganda*

P-036 A 16-Year Prospective Survey of Mycobacterium Xenopi, Mycobacterium Kansasii and Mycobacterium Fortuitum Infection in Patients with HIV Disease

Roberto Manfredi (1)*

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-037 Vitamin D and HIV: Implications for Chronic Disease Management

Toby Dyer (1)* Virginia Cafaro (1) Valby Chow (1)

(1) *SHARED PERSPECTIVES ON THERAPIES (SPOT), San Francisco, USA*

P-038 Abstract Assessment of Knowledge, Attitude and Risk Practice for HIV Infection among Male Prisoners: The Case Maweni Prison, Tanga Region Tanzania

Joan Karomba (1)*

(1) *Muhimbili National Hosp, Dar es saalam, Tanzania, United Republic of*

P-039 Clinical and Immunological Presentation of New HIV-Infected Patients in an Outpatient Clinic

Edna Quintas (1) Sara Cardoso (1)* Carmela Pineiro (1) Danina Ferreira (1) Rosario Serrao (1) Jorge Soares (1) Rui Marques (1) Antonio Sarmiento (1)

(1) *Infectious Diseases. Hospital Sao Joao, Porto, Portugal*

P-040 An HIV-Infected Patient with Associated, Lethal Rhinopharyngeal Actinomycosis and a Rapidly Progressing Local Adenocarcinoma

Roberto Manfredi (1)* Sergio Sabbatani (1) Ciro Fulgaro (1)

(1) *Infectious Diseases, S. Orsola Hospital, Bologna, Italy*

P-041 More than Ten Years without any Detectable HIV Viremia: Exceptionally Long-Term Non-Progressive HIV Infection

Roberto Manfredi (1)* Sergio Sabbatani (1) Giovanni Fasulo (1) Ciro Fulgaro (1)

(1) *Infectious Diseases, S. Orsola Hospital, Bologna, Italy*



► B2: HIV, Therapy

- P-042** Antiretroviral Treatment and Expression of the mRNA Levels for PGP, MRP1, MRP4 and MRP5 in HIV Antiretroviral Naïve Patients. Follow-Up at 48 Weeks.
Francesca Falasca (1) Francesca Graziano (1) Laura Antonelli (2) Paola Maida (1) Claudia Montagna (1) Bambina Rizzo (1) Vincenzo Renda (2) Guido Antonelli (1) Ombretta Turriziani (1)*
(1) Department of Experimental Medicine, Virology Section, Sapienza University, Rome, Italy (2) Department of Infectious Diseases Umberto I Hospital, Rome, Italy
- P-043** Clinical and Immunological Outcomes among Adult Patients Receiving Antiretroviral Therapy (ART) at an HIV/AIDS Program in Uganda
Simon Muhumuza (1)* Julius Ssempiira (1) Fred Semitala (1) Jennifer Namusoby (1) Joseph Ouma (1) Enid Mbabazi (1) Moses Kamya (1)
(1) Mulago-Mbarara Teaching Hospital's Joint AIDS Program (MJAP), Kampala, Uganda
- P-044** Recombinant Soluble CCR5 and CXCR4 Chemokine Receptors as Anti-HIV Drug Targets
Victoria Kurbatska (1, 2)* Zhanna Rudevica (1, 2) Alexander Tsimanis (3) Ainars Leonciks (1, 2)
(1) Latvian Biomedical Research and Study center, Riga, Latvia (2) ASLA Biotech, Riga, Latvia (3) Bioactivity Ltd., Rehovot, Israel
- P-045** Two Recent, Fixed Associations of Antiretroviral Nucleos(T)ide Analogues. A Prospective Assessment of their Therapeutic use in HIV Disease Management. A Field Study
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-046** Factors Associated with Non-Adherence to HAART in HIV-Positive Pregnant Women During Pregnancy, Peri- and Postpartum in Lima, Peru
Romina Tejada (1)* Jorge Alarcón (1) Carlos Velásquez (2) César Gutiérrez (1)
(1) Instituto de Medicina Tropical, UNMSM, Lima, Peru (2) Instituto Nacional Materno Perinatal, Lima, Peru
- P-047** Treatment of HIV-2 Infection with Ritonavir/Lopinavir: Results at 60 Months. A Single-Center Study of 9 Patients
Philippe Genet (1)* Tahar Touahri (1) Laurence Courdavault (1) Frédérique Plassart (1) Juliette Gerbe (1)
(1) CH Victor Dupouy, Argenteuil, France
- P-048** Efficacy and Tolerability of RAL, MVC and ETV Used in Combination in the Treatment of Highly Treatment Experienced HIV Infected Patients
Shilpa Sayana (1) Homayoon Khanlou (1)*
(1) AIDS Healthcare Foundation, Los Angeles, USA
- P-049** Outcome of 1st Line Antiretroviral Therapy (ART) with Respect to Treatment Failure at Art Centre, B. J. Medical College, Civil Hospital, Ahmedabad
Bipin Amin (1)* Urvi Derasari (1) Umesh Nihalani (1) Hemang Purohit (1) Manoj Shevkani (1) Sanjeev Prajapati (1) Girish Prajapati (1) Bankim Mankad (1) Asha Shah (1) Burzin Kavina (1)
(1) ART center B J Medical College, Ahmedabad, India
- P-050** Analysis of Protease Treatment-Associated Mutations in a Group of HIV-1 Subtype F Infected Individuals with Two Sequences Obtained in Different Time Points
Márcia Perez Resende Oliveros (1, 3)* Clarice Gameiro da Fonseca Pachi (2) Jorge Futoshi Yamamoto (2) Elizabeth Cavalieri (3) Maria Cecilia Araripe Sucupira (3) Luis Fernandez Lopez (1, 4) Ricardo Sobhie Diaz (3)
(1) School of Medicine, University of São Paulo – LIM 01 - HCFMUSP, Sao Paulo, Brazil (2) ANSP- Academic Network of São Paulo, Sao Paulo, Brazil (3) Federal University of São Paulo – Retrovirology Laboratory, Sao Paulo, Brazil (4) CIARA – [Center for Internet Augmented Research and Assessment] – Florida International University, Miami, USA

- P-051** Efficacy and Safety of TDF+FTC+EFV in Naïve Patients Initiating HAART; an Observational Study Comparing Atripla vs Truvada/Sustiva Exposure.
Carlos Alberto Sanchez (1)* Jose Medrano (1) Pablo Labarga (1) Eugenia Vispo (1) Aida Calviño (1) Luz Martín-Carbonero (1) Pablo Barreiro (1) Vicente Soriano (1)
(1) Hospital Carlos III, Madrid, Spain
- P-052** Fusion Inhibitors and their Evolving Role During Salvage Antiretroviral Therapy. Seven Years of Experience with Enfuvirtide
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-053** Our Experience in 2nd Line Anti Retroviral Therapy (ART) at State AIDS Clinical Expert Panel (SACEP) Clinic, Centre of Excellence (CoE), Art Centre, B. J. Medical College, Civil Hospital, Ahmedabad
Bankim Mankad (1)* Hemang Purohit (1) Asha Shah (1) Manoj Shevkani (1) Burzin Kavina (1) Bipin Amin (1) Umesh Nihalani (1) Sanjeev Prajapati (1) Urvi Derasari (1) Girish Prajapati (1)
(1) ART center B J Medical College, Ahmedabad, India
- P-054** Treatment Outcomes in Patients Receiving Combination Antiretroviral Therapy
Kenneth Agu (1)* Uche Ochei (1) Azuka Oparah (1) Obialunamma Onoh (2)
(1) Department of Clinical Pharmacy and Pharmacy Practice, University of Benin, Benin, Nigeria (2) West African Postgraduate College of Pharmacists, Lagos, Nigeria
- P-055** Lopinavir/R + Efavirenz Combination as a Potent NRTI Sparing Antiretroviral Therapy.
Philippe Henrivaux (1)* Yvette Fairon (2) Benoît Kabamba (3) Jean-Cyr Yombi (4) Patrick Goubau (3) Bernard Vandercam (4)
(1) CHC Clinique St Joseph, Médecine Interne, Liège, Belgium (2) ASBL, Liège, Belgium (3) Laboratoire de Référence SIDA, Cliniques Universitaires Saint Luc, Brussels, Belgium (4) Centre de Référence SIDA, Cliniques Universitaires Saint Luc, Brussels, Belgium
- P-056** Experience with Art Adherence Counselling at Muhimbili National Hospital, Dar Es Salaam, Tanzania
Joan Karomba (1)*
(1) Muhimbili National Hosp, Dar Es Salaam, Tanzania, United Republic Of
- P-057** Interventions to Promote Adherence to Antiretroviral Therapy (HAART) among Adult Patients at an HIV/AIDS Program in Uganda:
Simon Muhumuza (1)* Violet Gwokyalya (1) Elizabeth Kutamba (1)
(1) Mulago-Mbarara Teaching Hospitals' Joint AIDS Program (MJAP), Kampala, Uganda
- P-058** Lowering HIV Fitness and Replication Rate by Administration of Lamivudine Alone, in Extensively Resistant HIV-Infected Patients, as a «Bridging» Strategy Towards Optimized Salvage Regimens
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-059** Impact of Maraviroc on Immune Restoration in an Advanced Stage HIV-Infected Patient
Sylvie Bregigeon (1) Amélie Menard (1) Olivia Faucher (1) Catherine Tamalet (2) Caroline Solas (3) Véronique Obry-Roguet (1) Isabelle Poizot-Martin (1)*
(1) Department of Immuno-hematology, HIV-Clinical center, Hospital SainteMarguerite, Marseilles, France (2) Fédération de Microbiologie Clinique, Hôpital de la Timone, Marseilles, France (3) Laboratoire de Pharmacocinétique et de Toxicologie, Hôpital de La Timone, Marseilles, France
- P-060** «Self-Managed», Inadequate «Adherence» to Antiretroviral Therapy, Limited to one Half of Standard Dosages, Followed by an Unexpected, Sustained Virological and Immunological Success
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-061 Without a Quality Management Tool, All HIV Managers Shall not Realise any Steps Forward for Improvement. A Taso Uganda Experience.

Denis Mpiima (1)* Ceasar Luzze (1) Nicholas Kizito (1, 1)

(1) *The AIDS Support Organisation, Kampala, Uganda*

B3: HIV, Side Effects

P-062 Cystatin C and Cardiovascular Risk in HIV Infected Patients

Katia Falasca (1) Claudio Ucciferri (1)* Paola Mancino (1) Francesca Vignale (1) Jacopo Vecchiet (1)

(1) *Infectious Disease Clinic, Department of Medicine and Science of Aging, G. d'Annunzio University, Chieti, Italy*

P-063 Effects on Insulin Sensitivity and Hepatic Safety of Atazanavir in HCV/HIV Coinfected Patients versus HIV Monoinfected. A Propective 48-Week Study.

Héctor Meijide (1) Álvaro Mena (1)* Ángeles Castro (1, 2) Pilar Vázquez (1) Soledad López (1) Joaquín Serrano (1) Laura Bello (1) José Pedreira (1)

(1) *HIV Unit, Internal Medicine Service. University Hospital of A Coruña, A Coruña, Spain* (2) *University of A Coruña, A Coruña, Spain*

P-064 Hypertension and Microalbuminuria in HIV Infected Patients: Beneficial Effects of the Treatment with Telmisartan

Claudio Ucciferri (1)* Paola Mancino (1) Katia Falasca (1) Francesca Vignale (1) Jacopo Vecchiet (1)

(1) *Infectious Disease Clinic, Department of Medicine and Science of Aging, "G. d'Annunzio" University, Chieti, Italy*

P-065 NRTIS (ZDV and D4T) Side Effects in PLHAS Attending the Antiretroviral Treatment Centre of B. J. Medical College and Civil Hospital at Ahmedabad, Gujarat, India

Umesh Nihalani (1)* Asha Shah (1) Burzin Kavina (1) Bipin Amin (1) Urvi Derasari (1) Hemang Purohit (1) Bankim Mankad (1) Sanjeev Prajapati (1) Girish Prajapati (1) Manoj Shevkani (1)

(1) *ART center B J Medical College, Ahmedabad, India*

P-066 Depression and Self-Esteem of Patients Positive for HIV / AIDS in an Inland City of Brazil

Carolina Castrighini (1) Elucir Gir (1)* Lis Neves (1) Renata Reis (2) Marli Galvão (3) Myeko Hayashido (1)

(1) *São Paulo University - School Of Nursing Ribeirão Preto, Ribeirão Preto, Brazil* (2) *Alagoas Federal University, Maceió, Brazil* (3) *Ceará Federal University, Fortaleza, Brazil*

P-067 A Young Patient with Perinatal HIV Infection Treated for 17 Consecutive Years with Antiretroviral Therapy: Extremely Severe Lipo-Accumulation Picture

Roberto Manfredi (1)*

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-068 Emerging HIV-Associated Concerns: Osteopenia and Osteoporosis. Easy Prevention and Management Guidelines

Roberto Manfredi (1)*

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*

P-069 Interactive Theatre for HIV/AIDS Side Effects on Youth Sexuality Reproductive Health and Rights in Pakistan to Learn and Practice

Sana Sohail (1)*

(1) *Chanan Development Association (CDA), Lahore, Pakistan*

► B4: HIV, Tumors

P-070 Interplay Between HIV and Micrnas in AIDS-Related Lymphomas

Giulia De Falco (1)* Anna Luzzi (1) Federica Morettini (1) Anna Onnis (1) Lorenzo Leoncini (1)

(1) Dept. Human Pathology & Oncology, University of Siena, Siena, Italy

P-071 Non-AIDS Related Malignancies 13 Years after the Availability of Combined Antiretroviral Therapy

Roberto Manfredi (1)*

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

► B5: HIV, Others

P-072 Prolonged Elevation of Viral Loads in HIV-1-Infected Children in a Region of Intense Malaria Transmission in Northern Uganda

Herbert Kiyingi (1, 2)* Thomas Egwang (1) Maria Nannyonga (2)

(1) medbiotech Laboratories, Kampala, Uganda (2) Nsambya Hospital, Kampala, Uganda

P-073 Women HIV Education, Capacity Building and Economic Empowerment Initiative

Caroline Agochukwu (1)*

(1) Health Matters Incorporated, Lagos, Nigeria

P-074 Tuberculosis with Pulmonary Involvement in HIV Patients

Lígia Fernandes (1)* Nuno Marques (2) Ana Lebre (2) Joaquim Oliveira (2) José Saraiva da Cunha (2) António Meliço Silvestre (2)

(1) Serviço de Pneumologia, Centro Hospitalar de Coimbra, Coimbra, Portugal (2) Departamento de Doenças Infecciosas, Hospitais da Universidade de Coimbra, Coimbra, Portugal

P-075 Service Outcome of Antiretroviral Post-Exposure Prophylaxis (PEP) for Occupational HIV Exposure among Health Care Personnel

Asha Shah (1)* burzin kavina (1) sanjeev prajapati (1) hemang purohit (1) manoj shevkani (1) urvi derasari (1) umesh nihalani (1) bipin amin (1) bankim mankad (1) girish Prajapati (1)

(1) ART center B J Medical College, Ahmedabad, India

P-076 Glomerular Filtration (GF) Determined by Creatinine Clearance (CCR) in 24 Hours Urine and Cockcroft & Gault (CG) and Modification of Diet in Renal Disease (MDRD) Equations in a Large Cohort of HIV+ Patients

Pablo Labarga (1)* Marta Albalade (2) Pablo Barreiro (1) Elena Alvarez (1) Luz Martín-Carbonero (1) Javier Pinilla (3) Eugenia Vispo (1) Jose Medrano (1) Carlos A Sanchez (1) Vicente Soriano (1)

(1) Hospital Carlos III, Madrid, Spain (2) Hospital Infanta Leonor, Madrid, Spain (3) Hospital San Pedro, Logroño, Spain

P-077 Factors Associated with Development of Opportunistic Infections among Patients on Art at a Ugandan Program-MJAP

Simon Muhumuza (1)* Joseph Ouma (1) Fred Semitala (1)

(1) Mulago-Mbarara Teaching Hospitals Joint AIDS Program (MJAP), Kampala, Uganda

P-078 Evaluation of the Therapeutic Educational Consultations of Patients Infected by the Human Immunodeficiency Virus (HIV)

Jennifer Grangé (1) Frederique Plassart (1)*

(1) Charles Foix Hospital, Ivry sur seine, France

P-079 CANCELLED



P-080 Immune Response Characterization in HIV/HCV Co-Infected Patients of Medicine Tropical Foundation

Adriana Malheiro (1, 3)* Liziara Silva Fraporti (1, 3) Flámir Victoria (2) Kátia Luz Torres (1) João Paulo Diniz Pimentel (1) Andrea Tarragô (1) Laura Patricia Viana Maia (1, 3) Felicien Vásquez (1) José Eduardo Levi (4) Marilu Victoria (2)

(1) Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil (2) Fundação de Medicina Tropical do Amazonas, Manaus, Brazil (3) Universidade Federal do Amazonas, Manaus, Brazil (4) Universidade Estadual de São Paulo, São Paulo, Brazil

P-081 Advocacy and Piloting the First Needle and Syringe Exchange Program in Iranian Prisons

Mohammad Shahbazi (1)* Marziyeh Farnia (1) Mohammadreza Keramati (1) Ramin Alasvand (1)
(1) Iran Prisons Organization, Tehran, Iran, Islamic Republic of

P-082 Small Intestine Enteroscopy: A New Diagnostic Tool not only in HIV Infection

Christian Traeder (1)* Julia Breitzkreutz (1) Keikawus Arastéh (1)

(1) Vivantes Auguste Viktoria Hospital, Berlin, Germany

► B6: Hepatitis, Therapy

P-083 Chronic HCV Treatment with Peginterferon-Ribavirin and Severe Tuberculosis Re-Activation

Roberto Manfredi (1)* Leonardo Calza (1)

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-084 Severe Psoriasis Emerged after Treatment of Chronic HCV Co-Infection with Pegylated-Interferon and Ribavirin, Supported by Neutropenia Rescue with Repeated Filgrastim Administration

Roberto Manfredi (1)* Sergio Sabbatani (1)

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

► B7: Hepatitis, Other

P-085 The Experience of Pain Among Patients Living with Hepatitis C: an Assessment of Prevalence and Needs

Christine Cabrera (1)* Kimberly Corace (2) Louise Balfour (2) George Tasca (2) Curtis Cooper (2) Jonathan Angel (2) William Cameron (2) Paul MacPherson (2) Gary Garber (2)

(1) University of Ottawa, Ottawa, Canada (2) The Ottawa Hospital-General Campus, Ottawa, Canada

P-086 Spontaneous HCV Clearance in a Patient with HIV Infection and a Concurrent, Never Treated, Evolutive HCV Hepatitis, after over Twenty Years of Chronic Co-Infection

Roberto Manfredi (1)* Nicola Dentale (1) Leonardo Calza (1)

(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

P-087 Preventive Behavior among Doctors with Respect to Hepatitis-B in Bolan Medical Complex Hospital, Quetta, Pakistan

Khalid Rehman (1)*

(1) Health, Quetta, Pakistan

► B8: STDs

P-088 Seroepidemiology of Infection with Herpes Simplex Virus Type 2 (Hsv2) among Asymptomatic Students Attending Islamic Azad University of Kazeroun, Southwest of Iran.

Daryoush Tayyebi (1)* Mojgan Tabatabaee (1) Marjan Rahsaz (2)

(1) Islamic Azad University-Kazeroun Branch, Kazeroun, Iran, Islamic Republic Of (2) Transplantation Research Center, Shiraz, Iran, Islamic Republic Of

P-089 CANCELED

► B9: Other, Clinical Science

P-090 Disturbance of HDL Apolipoprotein AI Metabolism in Severe Hyperlipidemic and Lipodystrophic HIV Patients on a Protease Inhibitor Treatment.

Khadija Ouguerram (1)* Yassine Zair (1) Stéphanie Billon (1) Michel krempf (1)

(1) INSERM U915, Nantes, France

P-091 Pulmonary and Disseminated Tubercular Disease by Bacillus of Calmette-Guérin after Administration as a Local Adjuvant Immunotherapy of Relapsing Bladder Adenocarcinoma

Roberto Manfredi (1)* Nicola Dentale (1)

(1) Infectious Diseases, S. Orsola Hospital, Bologna, Italy

P-092 Educational Intervention and HIV Infection: Preliminary Results.

Sylvie Bregigeon (1)* Brigitte Canet (1) Véronique Obry-Roguet (1) Amélie Menard (1) Isabelle Poizot-Martin (1)

(1) 1department Of Immuno-Hematology, Hiv-Clinical Center, Hospital Sainte Marguerite, Marseilles, France

P-093 Incidence Rate of Nosocomial Urinary Tract Infections in Intensive Care Unit Patients of Zanjon's Shafeeieh Hospital

Vida Sadeghzadeh (1)*

(1) Islamic Azad University ,Zanjan Branch , Zanjan, Iran, Islamic Republic Of

P-094 Hospital Based Palliative Care Approach TO HIV/AIDS- A Nigeria Experience

Folaju Olusegun Oyebola (1)*

(1) Pain And Palliative Medicine Department. Federal Medical Centre Idi-Aba. P.M.B 3031,Sapon P.O., Abeokuta, Nigeria

C Epidemiology & Prevention

► C1: HIV, Epidemiology & Prevention

P-095 Destruction HIV Viral RNA by siDNA Triggering RNase H

Karin Moelling (1)*

(1) University , Zurich, Switzerland

P-096 A Research Report on «Positive Prevention» Intervention in Two Ethnic Habitats along the Border with Myanmar in Yunnan

Yan Guo (1) F Bin Su (1)*

(1) Yunnan Daytop Drug Abuse Treatment and Rehabilitation Center, Kunming, China

P-097 Results from a Multimedia Testing and Counseling Program in an Urban Emergency Department

Yvette Calderon (1, 2)* Ethan Cowan (1, 2) Jade Fettig (1) Karachi Egbuta (1) Jason Leider (1, 2)

(1) Jacobi Medical Center, New York, USA (2) Albert Einstein College of Medicine, New York, USA

- P-098** Recent HIV Infection among Newly Diagnosed with HIV Cases in Turin, Italy
 Mariangela Raimondo (1)* Chiara Pasqualini (2) Valeria Ghisetti (3) Vincenza Regine (1) Laura Camoni (1) Maria Cristina Salfa (1) Barbara Suligo (1)
(1) Istituto Superiore di Sanità, Rome, Italy (2) SEREMI ASL 20, Alessandria, Italy (3) Amedeo di Savoia Hospital, Turin, Italy
- P-099** HIV/AIDS Epidemic Features and Trends in Setif City (Algeria) From 1986 to 2009
 Amel Ouyahia (1)* Mounira Rais (1) Abdelkader Gasmi (1) Wahiba Guenifi (1) Salah Mechakra (1) Abdemadjid Lacheheb (1)
(1) faculte de medecine centre hospitalo universitaire , setif, Algeria
- P-100** HIV-Related Risk Factors among Male Sex Workers in Different Settings in Shenzhen, China
 Jin Zhao (1, 2)* Wen-De Cai (2) Lin Chen (2) Yong-Xia Gan (2) Yun-Yun Zi (2) Jin-Quan Cheng (2) Xiao-Rong Wang (1) Ming-Liang He (1)
(1) School of Public Health of Primary Care, The Chinese University of Hong Kong, Hong Kong , Hong Kong (2) Shenzhen Center for Disease Control and Prevention, Shenzhen, China
- P-101** The Trend of HIV/AIDS Prevalence among IDU's in Iranian Prisoners (1376-1386)
 Mohammad Shahbazi (1)* Marziyeh Farnia (1) Ghobad Moradi (1) Bahman Ebrahimi (1)
(1) GFATM(theglobalfund.org) - Iran Prisons Organization, Tehran, Iran, Islamic Republic of
- P-102** HIV Infection Newly Diagnosed in Northern Italy. Evolving Trends
 Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-103** Men who Have Sex with Men(MSM) and HIV Epidemic in China: A Web-Based Study on MSM
 Jianmin Xing (1) Konglai Zhang (2)*
(1) Beijing University of Chinese Medicine, Beijing, China (2) Peking Union Medical College, Beijing, China
- P-104** CANCELLED
- P-105** Killer Immunoglobulin-Like Receptor Genes and Heterosexual HIV-1 Transmission
 Aimee Merino (1)* Rakhi Malhotra (1) Matt Morton (1) Joseph Mulenga (2, 3) Susan Allen (2, 3) Eric Hunter (3) Jianming Tang (1) Richard Kaslow (1)
(1) UAB, Birmingham, USA (2) Rwanda-Zambia HIV Research Group, Lusaka, Zambia (3) Emory, Atlanta, USA
- P-106** Non-Injected Illicit Drugs and Alcohol and HIV-Related High-Risk Sexual Behaviors in a Street-Recruited Sample of Non-Injecting Drug Users in New York City
 Ashutosh Mishra (1)* Daniel Pilowsky (1) Judith Jacobson (1)
(1) Columbia University, New York, USA
- P-107** A Validated Stigma Scale Measures Decreased HIV-Related Stigma Among Men in a Community-Based HIV Prevention Services Program in Rural Maharashtra, India.
 Ashok Dyalchand (1)*
(1) Institute of Health Management, Pachod, Pune, India
- P-108** Difficulties of Routine Rapid HIV Screening in Emergency Department
 Philippe Genet (1)* Catherine Legall (1) Pascal Peudepiece (1) François Briand (1) Laurence Courdavault (1)
(1) CH Victor Dupouy, Argenteuil, France
- P-109** CANCELLED

- P-110 Subacute and Rehabilitation Care Facilities « Soins de Suite et De Réadaptation (SSR) », Dedicated to HIV Patients in Marseilles, France**
Jean-Paul Dimet (1) Gabrielle Vinai (1) Berengère Labarrière (1) Loïc Julien (1) Eliane Lerda (1) Nadia Timezouaght (1) Nathalie Petit (1)*
(1) Polyclinique La Feuillaie, Marseille, France
- P-111 Identifying Practices and Strategies to Increase HIV Testing among Haitian Migrant Communities**
Jonathan Santiago (1, 2)*
(1) Agence de la santé et des services sociaux de Montréal, Montréal, Canada(2) University of Washington School of Public Health, Seattle, USA
- P-112 HIV/AIDS Epidemic in Belarus**
Vladimir Eremin (1)* Elena Gasich (1) Sergei Eremin (1) Ekaterina Ambarcumian (1) Vladimir Lukashov (3)
(1) Research Institute for Epidemiology & Microbiology, Minsk, Belarus(2) D.I. Ivanovsky Institute of Virology, Moscow, Russian Federation(3) Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- P-113 Cervical Dysplasia in Postmenopausal Patients Infected by HIV.**
Pierre-François Ceccaldi (1, 2)* Claudia Ferreira (1) Florence Coussy (1) Charlotte Mechler (1) Catherine Crenn-Hebert (1) Laurent Mandelbrot (1)
(1) AP-HP Louis Mourier, Colombes, France(2) AP-HP Beaujon, Clichy, France
- P-114 CANCELLED**
- P-115 Knowledges, Attitudes and Practices in University Students about Sexual and Reproductive Health and HIV/AIDS in Bogotá D.C., Colombia**
Oscar David Diaz-Sotelo (1)*
(1) Universitat Autònoma de Barcelona, Barcelona, Spain(2) RANDOM Foundation, Bogotá D.C., Colombia
- P-116 Transition to Adult Clinics in Youth Living with HIV since Birth**
Mylène Fernet (1)* Marie-Eve Richard (1) Joseph Josy Lévy (1) Joanne Otis (1) Lapointe Normand (2) Samson Johanne (2) Guylaine Morin (2) Kimberly Wong (1) Jocelyne Thériault (1) Germain Trottier (3)
(1) Université du Québec à Montréal, Montréal, Canada (2) CHU Ste-Justine, Université de Montréal, Montréal, Canada(3) Université Laval, Québec, Canada
- P-117 Knowledge and Attitudes on HIV/AIDS and Sexual Behaviour among Male Soldiers in Sri Lanka Army**
Saveen Semage (1)* Sujatha Samarakoon (2)
(1) Sri Lanka Army Medical Services, Colombo, Sri Lanka(2) National STD/AIDS Control Program, Ministry of Healthcare & Nutrition Sri Lanka, Colombo, Sri Lanka
- P-118 Female Condom in HIV/AIDS Prevention among Female Commercial Sex Workers in Nigeria: A Geographical Perspective**
Emmanuella Onyenechere (1)*
(1) Imo State University, Owerri, Nigeria
- P-119 Human Immunodeficiency Virus Viral Markers Seroprevalence in First-Time Healthy Blood Donors Referred to Transfusion Centers of Bushehr Province, South of Iran (April2004 to March2008)**
Hesam_oddin Maneshi (1)* Mojtaba Karimi (2) Shahab Zare (1) Gholam Reza Hajiani (2)
(1) Bushehr University of Medical Sciences - Student's Research Committee, Bushehr, Iran, Islamic Republic of(2) Bushehr Blood transfusion organization, Bushehr, Iran, Islamic Republic of



- P-120** **Correlates of HIV Knowledge and Sexual Risk Behaviors among Female Military Personnel**
Ekere Essien (1)* Osaro Mgbere (1, 2) Ernest Ekong (1, 3) Susan Abughosh (1) Emmanuel Monjok (1)
(1) University of Houston, Houston, USA (2) Houston Department of Health and Human Services, Houston, USA (3) Institute for Health Research and Development, Lagos, Nigeria
- P-121** **Ethnological Inquiry into Sexual Behaviours at Risk to Homosexuals in Portugal**
Marta Maia (1)* Khalid Fekhari (2)
(1) CRIA - ISCTE, Lisbon, Portugal (2) Instituto Piaget, Viseu, Portugal
- P-122** **Stigma and HIV Risk Behaviors of Transgender Women in Nepal: Implications for HIV Prevention**
Erin Wilson (1)* Sunil Babu Pant (2)
(1) Center for AIDS Prevention Studies, San Francisco, USA (2) Blue Diamond Society, Kathmandu, Nepal
- P-123** **Seroprevalence of Hepatitis B- Surface Antigen among Non-Professional Blood Donors in Selected Hospital in Dhaka City.**
Rezaul Karim (1)*
(1) NIPSOM, DHAKA, Bangladesh
- P-124** **HIV Prevalence Among TB Patients Attending Dots Centres in Rural Haryana, India**
Ravi Kumar Balu (1)* Sanjay Rai (1) Shashi Kant (1) Krishnan Anand (1) Lalit Dar (1) Urvashi Singh (1)
(1) All India Institute of Medical Sciences, New Delhi, India
- P-125** **Factor Associated with Getting HIV Tested for Infant whose Born from HIV Infected Mothers, Thailand : 2008**
Pradabporn Duangajna (1)*
(1) Office of Disease Prevention and Control Region 3 Chonburi Thailand, Chonburi, Thailand
- P-126** **Condom Use and Sexual Partnerships among Truck Drivers in Southern Brazil**
Daniela Knauth (1) Andréa Fachel Leal (1) Flavia Pilecco (1)*
(1) UFRGS, Porto Alegre, Brazil
- P-127** **CANCELLED**
- P-128** **HIV Infection and the Immigration in Italy. Consequences on Inpatient Hospitalizations and Day-Hospital Admissions at a Metropolitan Hospital, during the Last Nine Years**
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-129** **The Implementation of EPP Software using HIV Prevalence Data from Studies Conducted in Greece**
Georgios Nikolopoulos (1)* Chryssa Tsiara (1) Chryssoula Botsi (1)
(1) Hellenic Centre For Diseases Control And Prevention, Amarausio, Greece
- P-130** **HIV/AIDS Related Knowledge and Attitude among Female Sex Workers in Tehran/Iran**
Saeid Madani Ghahfarokhi (1)* Ameneh Setareh Forouzan (1) Payam Roshanfekar (1, 1, 1) Mohamad Ali Mohammadi (1) Masoumeh Dejman (1) Meroeh Vameghi (1) Mirtaheer Mousavi (1) Hassan Rafiee (1) Mansoureh Hemmasian Etefagh (1) Malihe Sheyani (2)
(1) Social Welfare and Rehabilitation Sciences University, Tehran, Iran, Islamic Republic of (2) social sciences department, Tehran, Iran, Islamic Republic of

P-131 CANCELLED

P-132 CANCELLED

P-133 Problem of Nosocomial Infection with Hepatitis B, C Viruses and HIV in Russian Dental Institutes. Review.

alexey shatokhin (1)*

(1) City AIDS Center, Moscow, Russian Federation

P-134 Feto-Maternal Outcomes in HIV Positive Pregnant Women: Pakistan PPTCT Experience

shazra abbas (1)* naveeda shabbir (1)

(1) National AIDS Control program Pakistan, Islamabad, Pakistan

P-135 An Analysis of Non Response in HIV Testing in India: Evidences from National Family Health Survey -3

Shri Kant Singh (1)*

(1) International Institute for Population Sciences, Mumbai, India

P-136 The Evaluation of Peer Education Workshops Efficacy on Knowledge of Non Medical Students About HIV/AIDS , Bushehr, South of Iran

Hesam_uddin Maneshi (1)* Ismaeil Asaadi (1)

(1) Bushehr University of Medical Sciences - Student's Research Committee, Bushehr; Iran, Islamic Republic of

P-137 Determinants Of the Willingness-To-Pay For HIV/AIDS Prevention: The Case Of Mother-To-Child Transmission In Selected Hospitals In Ghana

Emmanuel Ayifah (1)*

(1) University of Ghana, Accra, Ghana

P-138 Knowledge and Attitudes of Students in an Offshore Caribbean Medical School Towards HIV/AIDS

Rotimi Orisatoki (1)* Oluwafemi Oguntibeju (1, 1)

(1) Spartan Health Sciences University, School of Medicine, Vieux Fort, Saint Lucia (2) Cape Peninsula University of Technology, Bellville 7535, South Africa

P-139 Creating a Supportive Environment is Very Important to Reduce STI, HIV/AIDS and Infectious Disease.

S.M Rezaul Islam (1)* Nahida Islam (1)

(1) SHED Foundation, Chittagong, Bangladesh

P-140 Civic Educating Rural Pregnant Mothers to Take Full Nevaripine Dose a Tool to Reducing HIV Prevalence in Malawi

Caleb Kondwani Faith Thole (1)*

(1) Global Hope Mobilization, Lilongwe, Malawi(2) International AIDS Society, Geneva, Switzerland (3) Equinet, Southern Africa, Zimbabwe

P-141 A Study of HIV/AIDS Related Knowledge and Attitudes amongst the Engineering College Students

Arjit Kumar (1)* Pankaj Bharadwaj (1) J.P Srivastava (1)

(1) Eras Lucknow Medical College And Hospital, Lucknow, India

P-142 Services Integration for Injection Drug Users on Antiretroviral Therapy for Management of HIV Epidemic in Estonia

Kaja-Triin Laisaar (1)* Anneli Uusküla (1) Anjali Sharma (2) Jack DeHovitz (2)

(1) Department of Public Health, University of Tartu, Tartu, Estonia (2) Downstate Medical Center, State University of New York, Brooklyn, USA

- P-143** The International Physical Activity Questionnaire Overestimates Moderate and Vigorous Physical Activity in Human Immunodeficiency Virus Compared with Accelerometry
Soula Fillipas (1, 2)* Flavia Cicuttini (1, 2) Catherine Cherry (1, 2, 3) Anne Holland (1, 4)
(1) The Alfred, Melbourne, Australia (2) Monash University, Melbourne, Australia (3) Burnet Institute, Melbourne, Australia (4) La Trobe University, Bundoora, Australia
- P-144** The Perception of Taxi Drivers in Southern Part of Saint Lucia, West Indies Towards HIV/AIDS and Condom Use
Rotimi Orisatoki (1)* Oluwafemi Oguntibeju (2)
(1) Spartan Health Sciences University, School of Medicine, Vieux Fort, Saint Lucia (2) Cape Peninsula University of Technology, Bellville 7535, South Africa
- P-145** Interventions and Strategy to Mitigate HIV Related Risk Behavior Among Young Men in India
Vipul Vipul (1)* Srikant Srikant (1)
(1) IIPS, Mumbai, India
- P-146** Increased Antenatal HIV Testing among Rural Pregnant Women: a Community-Based HIV Prevention Services Program in Rural Maharashtra, India.
Ashok Dyalchand (1)* Gita Sinha (1)
(1) Institute of Health Management Pachod , Pune , India
- P-147** Effect of Materials on HIV/AIDS by the Different Segment of Population in a Selected Community Area.
Rezaul Karim (1)*
(1) NIPSOM, DHAKA, Bangladesh
- P-148** Assessing Risk Criteria and HIV Prevalence in Antenatal Clinic Clients from 2 Urban Tertiary Hospitals in Pakistan
Naveeda Shabbir (1)* Qudsia Uzma (1) Shazra Abbass (1)
(1) National AIDS Control Programme, Islamabad, Pakistan
- P-149** Develop IEC Material by PLHA to Lead a Positive Life.
Santosh Chettri (1)*
(1) National Association of People living with HIV/AIDS in Nepal (NAP+N), Kathmandu, Nepal

► C2: Hepatitis, Epidemiology & Prevention

- P-150** Service Integration of Blood Borne Viral Infections in HIV/AIDS Prevention Sites
Steven McCadney (1)*
(1) Yeshiva University, New York City, USA
- P-151** HBV and HCV Viral Markers Seroprevalence in First-Time Healthy Blood Donors Referred to Transfusion Centers of Bushehr Province, South of Iran (April 2004 to March 2008)
Hesam_oddin Maneshi (1)* Shahab Zare (1) Mojtaba Karimi (2) Gholam Reza Hajiani (2)
(1) Bushehr University of Medical Sciences - Student's Research Committee, Bushehr, Iran, Islamic Republic of (2) Bushehr Blood transfusion organization, Bushehr, Iran, Islamic Republic of
- P-152** Protecting at Risk Cadres of Health Workers from Medical Transmission of HIV and Hepatitis B and C Through Injection Safety Interventions
Susana de la Torre (1) Innoncent Gasimbi (2)* Deepa Bhat (1) Jessica Posner (1) Megan Noel (1) Victoria Masembe (2) Jackson Songa (3) Iqbal Hossain (1)
(1) John Snow Inc., Arlington, USA (2) John Snow Inc., Kampala, Uganda (3) John Snow, Inc., Nairobi, Kenya

- P-153** Awareness about Hepatitis B Infection among the Grass Root Level Health and Family Planning Workers in a Selected Health Complex at Dhaka District.
Rezaul Karim (1)*
(1) NIPSOM, Dhaka, Belarus
- P-154** Seroprevalence of Hepatitis B-Surface Antigen Among Selected Group of Population
Rezaul Karim (1)*
(1) NIPSOM, Dhaka, Bangladesh
- **C3: Other, Epidemiology & Prevention**
- P-155** Home Visiting to an HIV Positive Patient Prior to Initiation of Haart Has Lasting Impact on Their Adherence. Taso Experience.
Emmanuel Odeke (1)* Ricky Jones Nyatia (1, 1) Peter Sekiranda (1, 1)
(1) The AIDS Support Organisation (TASO), Kampala, Uganda
- P-156** Prevention by Care and Treatment of HIV-Positive Pregnant Woman in Côte D'ivoire
Kouamé Hervé Aka Prao (1)* Nicole Dakoury (1, 1) Pety Touré (1, 1) Nafissa Diakité (1) Koko Régina Konan (1) Marie-france Coulibaly Anaky (1) Siaka Touré (1, 1) Irma Ahoba Bobo (2)
- P-157** A Model to Determine Effective HIV/AIDS and Multi-Drug Tuberculosis (MDRTB) Treatment Policies: A Case Study from the Russian Federation
Reda Lebcir (1)*
(1) University of Hertfordshire, Hatfield, UK
- P-158** Sexual Behaviours and Drug Use among the Street Children
Shyam Lamsal (1)*
(1) B.P.Koirala Institute of Health Sciences, Dharan, Nepal
- P-159** Hospitalization Potential at an Infectious Diseases Division of a Metropolitan Hospital of Northern Italy. Persisting Limitations and Related Problems
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-160** HIV/AIDS and Human Rights in Legislation of the Republic of Serbia
Miljana Grbic (1)* Vojin Dimitrijevic (2) Nenad Petkovic (3) Ana Maricic (4) Judita Reichenberg (5) Jelena Zajeganovic (5) Milos Stojanovic (1) Rade Grbic (6)
(1) UNAIDS, Belgrade, Serbia (2) Beogradski centar za ljudska prava, Belgrade, Serbia (3) Q-klub, Belgrade, Serbia (4) Ministry of Justice, Belgrade, Serbia (5) UNICEF, Belgrade, Serbia (6) Medical Faculty Pr, Pristina, Serbia
- P-161** Supporting Homeless People Living with HIV
Ailsa Cameron (1)*
(1) University of Bristol, Bristol, UK
- P-162** Difficulties to Implement a Support Group for HIV Patients
Julia Artur (1)* Philippe Genet (1) Agathe Pigeon (1) Tahar Touarhi (1)
(1) CH Argenteuil, Argenteuil, France

D Pharmacology

► D1: HIV, New Drugs

P-163 Allosteric Regulation by Non Peptidic, Low Molecular Weight Compounds of CCR5 Coupling to G-Proteins and Interaction with GP120 - Consequences on Inhibition of R5 HIV-1 Infection.

Patricia Rueda (1)* Javier Garcia-Perez (1, 2) Isabelle Staropoli (1) Esther Kellenberger (3) José Alcamí (2) Fernando Arenzana-Seisdedos (1) Bernard Lagane (1)

(1) Institut Pasteur, Paris, France (2) Instituto de Salud Carlos III, Madrid, Spain (3) Université Louis Pasteur, Strasbourg, France

P-164 Modulations of Human Placental Transfer of Lopinavir, Ritonavir and Enfuvirtide.

Pierre-François Ceccaldi (1, 2, 3)* Laurent Mandelbrot (3) Claudia Ferreira (3) Robert Farinotti (1) Francois Forestier (1) Sophie Gil (1)

(1) Department of Clinical Pharmacy, University Paris-Sud 11, IFR141, School of Pharmacy, Châtenay-Malabry, France (2) Department of Obstetrics and Gynecology, Beaujon Hospital, AP-HP, Clichy, France (3) Department of Obstetrics and Gynecology, Louis Mourier Hospital, AP-HP, Colombes, France

P-165 CANCELLED

P-166 Duration of Antiretroviral Regimens in Treatment-Experienced Patients in Clinical Practice

Vicente Escudero Vilaplana (1)* Sergio Plata Paniagua (1) Nicolas Trovato Lopez (1) Isabel Castillo Romera (1) Arantza Ais Larisgoitia (1) Jose Maria Bellon Cano (1) Maria Sanjurjo Saez (1)

(1) Hospital General Universitario Gregorio Marañón, Madrid, Spain

► D3: Therapeutic Drug Monitoring

P-167 A Model Using Adherence: House Compliance Center Oasis AAS

Abdoulazziz Soundiata Traoré (1)*

(1) Association African Solidarité, Ouagadougou, Burkina Faso

E Emerging Infectious Diseases

► E1: Laboratory Aspects

P-168 Scorpion Model of Influenza A/H1N1: Hemagglutinin (Ha) Contains A Scorpion Toxin, Binding To Voltage-Gated Sodium Na⁺ Channel: Na⁺ Channel Inhibitors as Therapy.

Guy Mong Ky Tran (1, 2)* Laurent Gerbaud (1) Adrien Caprani (2)

(1) University of Auvergne, Hotel-Dieu Hospital, Clermont-Ferrand, France (2) Association POSITIFS, Paris, France

P-169 Development of a Test System for Simultaneous Detection of HIV RNA and Hepatitis C Virus (HCV) and DNA of Hepatitis B Virus (HBV) in Blood Samples

Nader Shahrokhi (1)* Masoud Hajia (2) Maysam Shahrokhi (2) Foroozan Abbasi (2) Mohamad Farzaneh-Khah (2)

(1) Pasteur Institute of Iran, Tehran, Iran, Islamic Republic of (2) Noor Medical Laboratory, Tehran, Iran, Islamic Republic of

P-170 Analyses Reveal a Novel Avirulent Streptococcus Suis Serotype 2 Strain that Induces Protective Immunity Against Challenge with the Highly Virulent Strains

Jiaqi Tang (1)*

(1) Department of Epidemiology, Research Institute for Medicine of Nanjing Command, Nanjing, China

- P-171** A Prospective Project of Microbiological Surveillance at a Teaching Hospital in Italy. Evolving Epidemiological Features, and in vitro Antimicrobial Sensitivity Trends
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-172** A Prospective Microbiological Surveillance in a Teaching Italian Hospital. Microbial Isolations and in vitro Antimicrobial Susceptibility Levels, and their Modifications Over Time
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, Bologna, Italy
- P-173** Auto-Immune Thrombocytopenia after Measles Mumps Rubella MMR Vaccination: Molecular Mimicry of Measles Virus Phosphoprotein with Platelet GPIIB.
Guy Mong Ky Tran (1, 2)* Laurent Gerbaud (1) Adrien Caprani (2)
(1) University of Auvergne, Hotel-Dieu Hospital, Clermont-Ferrand, France (2) Association Positifs, Paris, France
- P-174** Urinary Tract Pathogens Among Inpatients at a Large Italian Tertiary Care Hospital. A Prospective Monitoring Study
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-175** Agents Causative of Sepsis-Bacteremia in a Four-Year Prospective Surveillance Study Carried Out at a Teaching Italian Hospital
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, Bologna, Italy
- **E2: Clinical Aspects**
- P-176** The Emerging and the Spread of the Fifth Plasmodium Responsible of Human Malaria: Plasmodium Knowlesi
Roberto Manfredi (1)* Sergio Sabbatani (1) Sirio Fiorino (1, 2)
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy (2) Department of Internal Medicine, Budrio, Italy
- P-177** Perceived Quality of Clinical Care Provided by Nurses to People Living with HIV at Four Taso Sites in Uganda
Kenneth Mugisha (1, 2)* Coutinho Alex (2)
(1) TASO, Kampala, Uganda (2) IDI, Kampala, Uganda
- P-178** An Increasing Pathomorphism of Pulmonary Tuberculosis. Is There a Therapeutic Role for Novel Antimicrobial Compounds Effective on Mycobacterium Tuberculosis?
Roberto Manfredi (1)* Sergio Sabbatani (1) Leonardo Calza (1)
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy
- P-179** Symptomatic, Prolonged Parvovirus B19 Infection and Accompanying Illness in Otherwise Healthy Adults
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, Bologna, Italy
- P-180** An Infectious Disease Day-Hospital Service in a Metropolitan Area of Northern Italy. Evolving Assistance Features in the Last Fifteen Years (1994-2008)
Roberto Manfredi (1)*
(1) Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

► E4: Other, Emerging Infectious Diseases

P-181 Is There Pre-Existing Cross-Reactivity to Influenza A(H1N1)2009 in a Tropical Population?

Kwai Peng Chan (1)* Yee Leng Lee (1) Xin Lai Bai (1) Siew Hoon Lim (1)

(1) Singapore General Hospital, Singapore, Singapore

P-182 Molecular Epidemiology of Chikungunya Strains in Singapore in 2008

Kim-Yoong Puong (1)* Kwai-Peng Chan (1)

(1) Singapore General Hospital, Singapore, Singapore

P-183 Synthesis of the Studies About the Transmission Cycle of Malaria in an Area of Very Low Incidence Outside the Amazon Region in Brazil

Crispim Jr Cerutti (1)* Aloisio Falqueto (1) Helder Ricas Rezende (4) Renata Soares (2) Isabel Alves (2) Delsio Natal (2) Paulo Roberto Urbinatti (2) Tasciane Yamasaki (2) Ana Maria Ribeiro de Castro Duarte (3) Rosely dos Santos Malafronte (2)

(1) Universidade Federal do Espírito Santo, Vitória, Brazil (2) Universidade de São Paulo, São Paulo, Brazil (3) Superintendência de Controle de Endemias, São Paulo, Brazil (4) SESA, Vitória, Brazil

P-184 Clinical Presentation of Influenza A (H1N1) Infection in a Local Emergency Department in Greece.

Evangelos Voudoukis (1) Athanasios Panoutsopoulos (1) Pappas Apostolos (1) Stofa Efthimia (1) Leventogianni Vassiliki (1) Mpoumpoukas Theodoros (1) Mylona Panagiota (1) Rozi Fotini (1) Andrianopoulos Ioannis (1) Andrianopoulos Georgios (1)*

(1) Department of internal medicine of General Hospital of Argos, Argos, Greece

P-185 Comparison Of A Novel Real-Time RT-PCR, NS1 Antigen Detection And Serology In Early Diagnosis Of Dengue In Travelers.

Eili Huhtamo (1)*

(1) University of Helsinki, Helsinki, Finland

P-186 Influence Of Water On The Circulation Of The West Nile Virus In Horses In Southern France

Sophie Pradier (1, 2)* Alain Sandoz (3) Gaëtan Lefebvre (3) Annelise Tran (4) Sylvie Lecollinet (5) Agnès Leblond (2, 6)

(1) Clinique équine ENVA, Maisons-Alfort, France (2) UR 346 Épidémiologie animale INRA, Saint Genès Champanelle, France (3) Tour du Valat, Arles, France (4) CIRAD Agirs, Montpellier, France (5) UMR 1161 Virologie INRA AFSSA ENVA, Maisons-Alfort, France (6) Clinéquine ENVL, Marcy l'étoile, France

P-187 An Outbreak Of Influenza A (H1N1) 2009 At Mae Fah Luang University, Chiang Rai Province, Northern Thailand

Tawatchai Apidechkul (1)*

(1) Mae Fah Luang University, Chiang Rai Province, Thailand

P-188 Adherence To The Treatment Of Individuals With The HIV/Tuberculosis Co-Infection: Integrative Review

Lis Neves (1) Renata Reis (2) Elucir Gir (1)* Patrícia Ribeiro (1)

(1) São Paulo University - School Of Nursing De Ribeirão Preto, Ribeirão Preto, Brazil (2) Alagoas University, Maceió, Brazil

P-189 HIV & Emerging Infectious Diseases In Mobile Populations In Europe

Anna-Paola de Felici (1)* Manuel Carballo (1) Sofiat M.Akinola (1)

(1) International Centre for Migration, Health and Development, Geneva, Switzerland



P-190 Serum Levels Of Inflammatory Cytokines In Leprosy Patients

Lúcia de Paula (1)* Isabella Motta Passos (1) Rossilene Conceição da Silva (1) Adriana Malheiro (2) George Allan Villarouco Silva (1) Máisa Porto dos Santos (1) Maria da Graça Souza Cunha (1)

(1) *Fundação Alfredo da Matta, Manaus, AM, Brazil* (2) *Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, AM, Brazil*

P-191 Detection Of Ovine Herpesvirus-2 In Swine Semen, Brazil

Erica Azevedo Costa (1)* Aline de Marco Viott (1) Glauber de Souza Machado (1) Maria Rosa Quaresma Bomfim (1) Fabiana Magalhães Coelho (1) Mauricio Resende (1) Roberto Mauricio Carvalho Guedes (1)

(1) *Universidade Federal de Minas Gerais, Belo Horizonte, Brazil*

P-192 Multiple, Concurrent Or Subsequent Dysreactive And Autoimmune Disorders. Potential Clinical-Patogenetic Correlations, And Systemic Infectious Complications

Roberto Manfredi (1)*

(1) *Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy*



AUTHORS INDEX INDEX DES AUTEURS

A	
Abbas S.	P-134
Abbasi F.	P-169
Abbass S.	P-148
Abbate I.	0-11
Abughosh S.	P-120
Adrien A.	P-111
Agochukwu C.	P-073
Agu K.	P-054
Ahoba Bobo I.	P-156
Ais Larisgoitia A.	P-166
Aka Prao K. H.	P-156
Alarcón J.	P-046
Alasvand R.	P-081
Albalate M.	P-076
Alcami J.	I-15, P-163
Alex C.	P-177
Allan Villarouco Silva G.	P-190
Allen S.	P-105
Almasi F.	P-016
Alvarez E.	P-076
Alves I.	P-183
Amabile T.	P-031
Amatya S.	P-003
Ambarcumian E.	P-112
Amin B.	0-14, P-049, P-053, P-065, P-075
Anand K.	P-124
Angel J.	P-085
Antonelli G.	P-042
Antonelli L.	P-042
Apidechkul T.	P-187
Apostolos P.	P-184
Appay V.	I-30
Araripe Sucupira M. C.	P-050
Arastéh K.	P-082
Araújo A. R.	P-031
Arenzana-Seisdedos F.	P-163
Argentini C.	P-029
Armstrong C.	0-08
Arribas J.	0-15
Artur J.	P-162
Asaadi I.	P-136
Aweeka F.	I-08
Ayifah E.	P-137
Azevedo Costa E.	P-191
B	
Back D.	I-10
Badsì E.	0-10
Bai X. L.	P-181
Baldanti F.	0-16
Balfour L.	P-085
Balu R. K.	P-124
Barreiro P.	0-13
Barreiro P.	P-051, P-076
Bartolini B.	0-11
Battaglia F.	0-06
Baumert T. F.	P-007
Bavari S.	P-004
Bello L.	P-063
Bellon Cano J. M.	P-166
Bergmann J. F.	0-10
Bertuccio M. P.	P-022
Bevilacqua G.	P-002
Bharadwaj P.	P-141
Bhat D.	P-152
Billon S.	P-090
Bianco F.	0-13
Blasi M.	P-029
Blazkova J.	0-04
Bonsel M.	P-023
Botsi C.	P-129
Botta M.	0-16
Bourinbaïar A.	P-030
Bourliere M.	I-24
Bourry O.	P-011
Bras M.	0-05
Bregigeon S.	P-059, P-092
Breitkreutz J.	P-082
Brenner B.G.	I-21
Brew B.	I-07
Briand F.	P-108

AUTHORS INDEX

INDEX DES AUTEURS

- Briand S.**..... I-03
- Brooks C.**..... I-28
- Bruselles A.**..... 0-11
- Buonaguro F.**..... I-22
- Buonaguro L.**..... I-33
- Burruano D. L.**..... P-001
- Busch M.P.**..... I-28
- C**
- Cabrera C.**..... P-085
- Cafaro V.**..... P-037
- Cai W. D.**..... P-100
- Cairo C.**..... 0-08
- Calderon Y.**..... P-097
- Calviño A.**..... P-051
- Calza L.**..... P-083, P-086, P-178
- Cameron A.**..... P-161
- Cameron W.**..... P-085
- Camoni L.**..... P-098
- Canet B.**..... P-092
- Capeau J.**..... I-06
- Capobianchi M. R.**..... 0-11
- Caprani A.**..... P-168, P-173
- Carballo M.**..... P-189
- Cardoso S.**..... P-039
- Carrilho C.**..... P-002
- Castillo Romera I.**..... P-166
- Castrighini C.**..... P-066
- Castro Á.**..... P-063
- Catellani S.**..... 0-06, P-025
- Catone S.**..... P-029
- Catteeuw D.**..... P-024
- Cau P.**..... I-29
- Cavalieri E.**..... P-050
- Ceccaldi P. F.**..... P-113, P-164
- Ceccherini-Silberstein F.**..... I-20
- Cerutti C. J.**..... P-183
- Chabert-Orsini V.**..... 0-12
- Chan K. P.**..... P-181, P-182
- Chen L.**..... 0-03, P-100
- Cheng J. Q.**..... 0-03, P-100
- Cherry C.**..... P-143
- Chettri S.**..... P-149
- Chionne P.**..... P-029
- Chirico C.**..... P-022
- Chow V.**..... P-037
- Cicuttini F.**..... P-143
- Cioni M. P.**..... P-002
- Clayton R.**..... P-024
- Coiras M.**..... I-15
- Conceição Da Silva R.**..... P-190
- Cooper C.**..... P-085
- Corace K.**..... P-085
- Corazza F.**..... P-026
- Corneau A.**..... I-32
- Coulibaly Anaky M. F.**..... P-156
- Courdavault L.**..... P-047, P-108
- Coussy F.**..... P-113
- Cowan E.**..... P-097
- Crenn-Hebert C.**..... P-113
- D**
- Dakoury N.**..... P-156
- Dalai S.**..... P-020
- Dalton H.**..... I-01
- Damesyn M.**..... 0-01
- Dar L.**..... P-124
- De Falco G.**..... P-070
- De Felici A. P.**..... P-189
- De La Torre S.**..... P-152
- De Marco Viott A.**..... P-191
- De Souza Machado G.**..... P-191
- Debre P.**..... I-32
- Deeks S.G.**..... I-28
- Dehovitz J.**..... P-142
- Dejman M.**..... P-130
- Dejucq-Rainsford N.**..... P-011
- Deleage C.**..... P-011
- Demetriou V. L.**..... P-028
- Denis H.**..... P-011

Dental C.	P-007	Farinotti R.	P-164
Dentale N.	P-086, P-091	Farnia M.	P-081, P-101
Derasari U.	0-14, P-049, P-053, P-065, P-075	Farzaneh-Khah M.	P-169
Dereuddre-Bosquet N.	I-32	Fasulo G.	P-041
Descoutures J. M.	P-078	Faucher O.	P-059
Dettori S.	P-029	Fausther-Bovendo H.	I-32
Diakit� N.	P-156	Favorov M.	0-09
Diaz-Sotelo O. D.	P-115	Fekhari K.	P-121
Dimet J. P.	P-110	Fenoglio D.	0-06, P-025
Dimitrijevic V.	P-160	Fernandes L.	P-074
Diniz Pimentel J. P.	P-031, P-080	Fernandez J. V.	0-13
Dmitry P.	P-030	Fernandez Lopez L.	P-050
Dos Santos Malafrente R.	P-183	Fernet M.	P-116
Drillet A. S.	P-023	Ferreira C.	P-113, P-164
Duangajna P.	P-125	Ferreira D.	P-039
Duchateau J.	P-026	Ferrera A.	P-025
Durando P.	P-025	Fettig J.	P-097
Dyal J.	P-020	Fillipas S.	P-143
Dyalchand A.	P-107, P-146	Fiorino S.	P-176
Dyner T.	P-037	Firaguay G.	P-007
		Fisher M.	I-04
		Flood J.	0-01
		Florentin J.	P-007
		Forestier F.	P-164
		Forouzan A. S.	P-130
		Fotini R.	P-184
		Fulgaro C.	P-040, P-041
		Futoshi Yamamoto J.	P-050
		G	
		Gallo R.	KL-1
		Galvo M.	P-066
		Gameiro Da Fonseca Pachi C.	P-050
		Gan Y. X.	P-100
		Garbelli A.	0-16
		Garber G.	P-085
		Garcia N.	P-031
		Garcia-Perez J.	P-163
		Gasich E.	P-112
		Gasimbi I.	P-152
		Gasmi A.	P-099
		Gasperini R.	P-025
E			
Ebrahimi B.	P-101		
Efthimia S.	P-184		
Egbuta K.	P-097		
Egwang T.	P-072		
Ekong E.	P-120		
Emu B.	I-28		
Eremin S.	P-112		
Eremin V.	P-112		
Escudero Vilaplana V.	P-166		
Essien E.	P-120		
F			
Facer M.	0-01		
Fachel Leal A.	P-126		
Fairon Y.	P-055		
Falasca F.	P-042		
Falasca K.	P-062, P-064		
Falchi F.	0-16		
Falqueto A.	P-183		

AUTHORS INDEX

INDEX DES AUTEURS

- Genet P.**..... P-047, P-078, P-108, P-162
- Genovese D.**..... P-029
- Georgios A.**..... P-184
- Gerbaud L.**..... P-168, P-173
- Gerbe J.**..... P-047
- Ghisetti V.**..... P-098
- Gil S.**..... P-164
- Giorgetti C.**..... 0-12
- Gir E.**..... P-066, P-188
- Gondois-Rey F.**..... 0-04, P-007, P-008
- Gonzalez-Lahoz J.**..... 0-13
- Goodier M.R.**..... I-14
- Goubau P.**..... P-055
- Gougeon M. L.**..... 0-05, 0-07
- Grangé J.**..... P-078
- Graziano F.**..... P-042
- Graziosi C.**..... P-021
- Grbic M.**..... P-160
- Grbic R.**..... P-160
- Guenifi W.**..... P-099
- Guglietta S.**..... P-021
- Guidotti G.**..... P-002
- Guillaume M. P.**..... P-026
- Guo Y.**..... P-096
- Gutiérrez C.**..... P-046
- Gwokyalya V.**..... P-057
- H**
- Hajia M.**..... P-169
- Hajiani G. R.**..... P-119, P-151
- Halfon P.**..... 0-12
- Hallenberger S.**..... P-024
- Hatano H.**..... I-28
- Hayashido M.**..... P-066
- He M. L.**..... 0-03, P-100
- Hejnar J.**..... 0-04
- Hemmasian Ettefagh M.**..... P-130
- Henrivaux P.**..... P-055
- Herrera D.**..... P-008
- Hill A.**..... 0-15
- Hill J.**..... 0-01
- Hirsch I.**..... 0-04, P-007, P-008
- Hoffmann S.**..... P-018
- Holland A.**..... P-143
- Hopewell P.**..... 0-01
- Hossain I.**..... P-152
- Hsue P.Y.**..... I-28
- Huhtamo E.**..... P-185
- Hunt P.**..... I-28
- Hunter E.**..... P-105
- Huskens D.**..... P-017
- I**
- Ientile R.**..... P-022
- Ioannis A.**..... P-184
- Islam S. R.**..... P-139
- Israelski D.**..... P-020
- Iversen P.**..... P-004
- J**
- Jacobson J.**..... P-106
- Jaye A.**..... P-009
- Jégou B.**..... P-011
- Jirathitikal V.**..... P-030
- Johanne S.**..... P-116
- Jonas E.**..... P-018
- Josy Lévy J.**..... P-116
- Julien L.**..... P-110
- K**
- Kabamba B.**..... P-055
- Kamya M.**..... P-043
- Kant S.**..... P-124
- Karim R.**..... P-123, P-147, P-153, P-154
- Karimi M.**..... P-119, P-151
- Karmali R.**..... P-026
- Karomba J.**..... P-038, P-056
- Kaslow R.**..... P-105
- Kassaye S.**..... P-020
- Katabira E.**..... P-035
- Katz A.**..... P-111
- Katzenstein D.**..... P-020
- Kavina B.** 0-14, P-049, P-053, P-065, P-075

Kellenberger E.	P-163	Leider J.	P-097
Keramati M.	P-081	Leoniciks A.	P-044
Kettoola S.	P-015	Leoncini L.	P-070
Khanlou H.	P-048	Lerda E.	P-110
Khiri H.	0-12	Levi J. E.	P-080
Kim S. S.	P-012	Levy V.	P-020
Kiyingi H.	P-072	Levy Y.	I-13
Kizito N.	P-061	Lim S. H.	P-181
Knauth D.	P-126	López S.	P-063
Konan K. R.	P-156	Lopez-Huerta M.R.	I-15
Kostrikis L. G.	P-028	Lovejoy C.	P-004
Kozal M.	I-19	Luiz Neves W.	P-031
Krempf M.	P-090	Lukashov V.	P-112
Kumar A.	P-141	Luz Torres K.	P-031, P-080
Kumar M.	P-013	Luzze C.	P-061
Kumarpillai G.	P-013	Luzzi A.	P-070
Kurbatska V.	P-044		
Kurth J.	P-024		
Kutamba E.	P-057		
L		M	
L. Rao S.	P-013	M.Akinola S.	P-189
La Porte C.	I-09	Macpherson P.	P-085
Labarga P.	0-13, P-051, P-076	Madani Ghahfarokhi S.	P-130
Labarrière B.	P-110	Maga G.	0-16
Lacheheb A.	P-099	Magalhães Coelho F.	P-191
Lagane B.	P-163	Magnano San Lio M.	P-002
Laisaar K. T.	P-142	Magnier J. D.	0-10
Lambotte O.	I-26	Maia M.	P-121
Lamsal S.	P-158	Maida P.	P-042
Landay A.L.	I-28	Malheiro A.	P-031, P-080, P-190
Lavens D.	P-024	Malhotra R.	P-105
Le Grand R.	I-32, P-011	Mallon P.	I-31
Le Tortorec A.	P-011	Mancino P.	P-062, P-064
Lebcir R.	P-157	Mandelbrot L.	P-113, P-164
Leblond A.	P-186	Maneshi H.	P-119, P-136, P-151
Lebre A.	P-074	Manfredi R.	P-033, P-034, P-036, P-040, P-041, P-045, P-052, P-058, P-060, P-067, P-068, P-071, P-083, P-084, P-086, P-091, P-102, P-128, P-159, P-171, P-172, P-174, P-175, P-176, P-178, P-179, P-180, P-192
Lecollinet S.	P-186	Mangeot-Mederle I.	I-32
Lee Y. L.	P-181	Mankad B.	0-14, P-049, P-053, P-065, P-075
Lefebvre G.	P-186	Marchetti I.	P-002
Legall C.	P-108		

AUTHORS INDEX

INDEX DES AUTEURS

- Margolis D.**..... I-17
Maricic A...... P-160
Marino N...... P-029
Marques N...... P-074
Marques R...... P-039
Martin J.N...... I-28
Martín-Carbonero L...... P-051, P-076
Martinez E...... I-05
Martinson J.A...... I-28
Masembe V...... P-152
Mauricio Carvalho Guedes R...... P-191
Mazeron M. C...... 0-10
Mazzotta F...... P-029
Mbabazi E...... P-043
Mbayiha H. A...... P-027
Mccadney S...... P-150
Mccune J.M...... I-28
Mechakra S...... P-099
Mechler C...... P-113
Medrano J...... 0-13, P-051, P-076
Meijide H...... P-063
Melendez L...... P-010
Meliço Silvestre A...... P-074
Melki M. T...... 0-05, 0-07
Mena Á...... P-063
Menard A...... P-059, P-092
Merino A...... P-105
Metadilogkul O...... P-030
Metcalfe J...... 0-01
Mgbere O...... P-120
Miro J.M...... I-25
Mishra A...... P-106
Moecklinghoff C...... 0-15
Moelling K...... P-095
Moetter J...... P-018
Mohammadi M. A...... P-130
Monjok E...... P-120
Montagna C...... P-042
Montes M. L...... 0-15
Moradi G...... P-101
Moreau M...... P-011
Morettini F...... P-070
Morin G...... P-116
Morton M...... P-105
Moscatelli C...... P-002
Motta Passos I...... P-190
Mousavi M...... P-130
Mpiima D...... P-061
Mugerwa R...... P-035
Mugisha K...... P-177
Muhumuza S...... P-043, P-057, P-077
Mulenga J...... P-105
Murdaca G...... 0-06
Muriaux D...... P-006
Musso A...... 0-06
- N**
- Namusobya J.**..... P-043
Nannyonga M...... P-072
Narciso P...... 0-11
Natal D...... P-183
Neves L...... P-066, P-188
Nguyen T...... I-03
Nicand E...... 0-10
Nicastri E...... 0-11
Nihalani U...... 0-14, P-049, P-053, P-065,
 P-075
Nikolopoulos G...... P-129
Noel M...... P-152
Normand L...... P-116
Norris P.J...... I-28
Nunès J. A...... P-007
Nuvor S. V...... P-009
Nyatia R. J...... P-155
- O**
- Obry-Roguet V.**..... P-059, P-092
Ocero A...... P-035
Ochei U...... P-054
Odeke E...... P-155
Oguntibeju O...... P-138, P-144
Olive D...... 0-04, P-007, P-008
Oliveira J...... P-074

Onnis A.	P-070	Pinilla J.	P-076
Onoh O.	P-054	Pittaluga A.	P-005
Onyenechere E.	P-118	Plassart F.	P-047, P-078
Oparah A.	P-054	Plata Paniagua S.	P-166
Orisatoki R.	P-138, P-144	Plaud M.	P-010
Orlovsky V.	P-030	Poggi A.	0-06, P-025
Otis J.	P-116	Poizot-Martin I.	P-059, P-092
Ouguerram K.	P-090	Poli G.	I-12
Ouma J.	P-043, P-077	Poonia B.	0-08
Ouyahia A.	P-099	Porcu-Buisson G.	0-12
Oyebola F. O.	P-094	Porto Dos Santos M.	P-190
P			
Palmer S.	I-16	Posner J.	P-152
Panagiota M.	P-184	Pradier S.	P-186
Panoutsopoulos A.	P-184	Prajapati G.	P-049, P-053, P-065, P-075
Pant S. B.	P-122	Prajapati S.	0-14, P-049, P-053, P-065, P-075
Pantaleo G.	P-021	Prakash M.	0-15
Paolucci S.	0-16	Profy A. T.	P-017
Parodi A.	P-025	Puliti A.	P-005
Pasqualini C.	P-098	Puong K. Y.	P-182
Patrick P.	0-04	Purohit H.	0-14, P-049, P-053, P-065, P-075
Paula L. D.	P-190	Q	
Pauline F.	0-05	Quaresma Bomfim M. R.	P-191
Pauza D.	0-08	Quintas E.	P-039
Pedreira J.	P-063	R	
Peelman F.	P-024	Radi M.	0-16
Pellicanò G.	P-022	Rafiee H.	P-130
Pénaranda G.	0-12	Rahsaz M.	P-088
Perez Resende Oliveros M.	P-050	Rai S.	P-124
Perez-Olmeda M.	I-15	Raimondo M.	P-098
Petit N.	P-110	Rais M.	P-099
Petkovic N.	P-160	Raiteri M.	P-005
Peudepiece P.	P-108	Rapicetta M.	P-029
Philippe H.	0-04	Rathod G.	0-14
Picerno I.	P-022	Regine V.	P-098
Piedimonte G.	P-022	Rehman K.	P-087
Pigeon A.	P-162	Reichenberg J.	P-160
Pilecco F.	P-126	Reis R.	P-066, P-188
Pilowsky D.	P-106	Renda V.	P-042
Pineiro C.	P-039	Resende M.	P-191

AUTHORS INDEX

INDEX DES AUTEURS

Rezza G.	I-02	Semage S.	P-117
Ribeiro De Castro Duarte A. M.	P-183	Semitala F.	P-043, P-077
Ribeiro P.	P-188	Serrano J.	P-063
Ricas Rezende H.	P-183	Serrao R.	P-039
Richard M. E.	P-116	Setti M.	0-06
Riedel D.	0-08	Severi P.	P-005
Rizzo B.	P-042	Shabbir N.	P-134, P-148
Rodriguez E.	P-010	Shah A.	0-14, P-049, P-053, P-065, P-075
Romeu R.	P-010	Shahbazi M.	P-081, P-101
Roques P.	P-011	Shahrokhi M.	P-169
Roshanfekar P.	P-130	Shahrokhi N.	P-169
Routy J.-P.	I-18	Shankar P.	P-012
Rowland-Jones S.	P-009	Sharapov M.	0-09
Rozera G.	0-11	Sharma A.	P-142
Rudevica Z.	P-044	Shatokhin A.	P-133
Rueda P.	P-163	Shen R.	P-023
S		Shevkani M.	0-14, P-049, P-053, P-065, P-075
S.Chandra P.	P-013	Sheyani M.	P-130
Sabbatani S.	P-040, P-041, P-084, P-176, P-178	Silva Fraporti L.	P-031, P-080
Sadeghzadeh V.	P-093	Sinclair E.	I-28
Saez-Ciron A.	I-27	Singh S. K.	P-135
Saidi H.	0-05, 0-07	Singh U.	P-124
Sajadi M.	0-08	Sinha G.	P-146
Salari K.	P-020	Skolasky R.	P-010
Salfa M. C.	P-098	Smith P. D.	P-023
Samarakoon S.	P-117	Soares J.	P-039
Sanchez C. A.	0-13, P-051, P-076	Soares R.	P-183
Sandoz A.	P-186	Sobhie Diaz R.	P-050
Sanjurjo Saez M.	P-166	Sohail S.	P-069
Sanson Le Pors M. J.	0-10	Solas C.	I-11, P-059
Santiago J.	P-111	Songa J.	P-152
Saraiva Da Cunha J.	P-074	Soriano V.	I-23, 0-13, P-051, P-076
Sarmiento A.	P-039	Soumelis V.	P-007
Satie A. P.	P-011	Souza Cunha M. D. G.	P-190
Satishchandra P.	P-013	Spataro P.	P-022
Sayana S.	P-048	Spigner C.	P-111
Schols D.	P-017	Srikant S.	P-145
Schwartz-Cornil I.	P-023	Srivastava J.	P-141
Sekiranda P.	P-155	Ssempiira J.	P-043
Sellier P.	0-10	Staropoli I.	P-163
		Stojanovic M.	P-160

Study Group M.	0-15
Su B.	P-096
Subramanya S.	P-012
Suligoï B.	P-098
Summa M.	P-005
Swenson D.	P-004

T

Tabatabaee M.	P-088
Taffon S.	P-029
Tamalet C.	P-059
Tang J.	P-105
Tang J.	P-170
Taponeco F.	P-002
Tarragô A.	P-031, P-080
Tasca G.	P-085
Tavernier J.	P-024
Tayyebi D.	P-088
Tejada R.	P-046
Terriou P.	0-12
Tesse S.	0-10
Theodoros M.	P-184
Thériault J.	P-116
Thole C. K. F.	P-140
Timezougat N.	P-110
Tommasi C.	0-11
Toni T.	I-21
Touarhi T.	P-047, P-078, P-162
Touré P.	P-156
Touré S.	P-156
Towfic G.	P-015
Traeder C.	P-082
Tran A.	P-186
Tran G. M. K.	P-168, P-173
Traoré A. S.	P-167
Trejbalova K.	0-04
Trottier G.	P-116
Trovato Lopez N.	P-166
Tsiara C.	P-129
Tsimanis A.	P-044
Tudor D.	P-023
Turriziani O.	P-042

U

Ucciferri C.	P-062, P-064
Urbinatti P. R.	P-183
Uusküla A.	P-142
Uyttendaele I.	P-024
Uzma Q.	P-148

V

Vameghi M.	P-130
Van Der Heyden J.	P-024
Van Lint C.	0-04
Van Schouwbroeck B.	P-024
Vandercam B.	P-055
Vásquez F.	P-080
Vassiliki L.	P-184
Vázquez P.	P-063
Vecchiet J.	P-062, P-064
Velásquez C.	P-046
Verdin E.	0-04
Vermeire K.	P-017
Viana Maia L. P.	P-031, P-080
Victoria F.	P-080
Victoria M.	P-080
Vieillard V.	I-32
Vignale F.	P-062, P-064
Vinai G.	P-110
Vipul V.	P-145
Visalli G.	P-022
Vispo E.	0-13, P-051, P-076
Voudoukis E.	P-184

W

Wainberg M.	I-21
Walle E. S. F.	P-002
Wang X. R.	P-100
Warfield K.	P-004
Warren T.	P-004
Watt J.	0-01
Wells J.	P-004
Westenhouse J.	0-01
Whittle H.	P-009

AUTHORS INDEX

INDEX DES AUTEURS

Willbold D.	P-018
Wilson E.	P-122
Wong K.	P-116

X

Xia Q.	0-01
Xing J.	P-103

Y

Yamasaki T.	P-183
Yang Z.	0-03
Ye C.	P-012
Yombi J. C.	P-055

Z

Zair Y.	P-090
Zajeganovic J.	P-160
Zare S.	P-119, P-151
Zhang K.	P-103
Zhao J.	0-03, P-100
Zi Y. Y.	P-100
Zimba I.	P-002
Zocchi M. R.	0-06, P-025

Wednesday 24 March / Mercredi 24 mars



SHAPPING THE FUTURE OF CO-INFECTIONS WITH NOVEL AGENTS / MODELER L'AVENIR DES CO-INFECTIONS À L'AIDE DE NOUVEAUX AGENTS

Wednesday 24 March - 13:00 - 14:00
(Callelongue Amphitheater) /

Mercredi 24 mars - 13:00 - 14:00
(Amphitéâtre Callelongue)

page 15



la médecine fondée sur les preuves.

STEERING FOR NEW STRATEGIES / METTRE LE CAP SUR DE NOUVELLES STRATÉGIES

Wednesday 24 March - 17:00 - 18:30
(Callelongue Amphitheater)

Mercredi 24 mars - 17:00 - 18:30
(Amphitéâtre Callelongue)

page 17

  In French only / En français seulement

Thursday 25 March / Jeudi 25 mars



UNE DIVISION DE  JANSSEN-CILAG



JANSSEN-CILAG

SWITCHING FROM STABLE REGIMEN: WHICH RISKS, WHICH BENEFITS ? / CHANGEMENT DE TRAITEMENT ANTIRÉTROVIRAL CHEZ LES PATIENTS EN SUCCÈS VIROLOGIQUE : QUELS RISQUES, QUELS BÉNÉFICES ?

Thursday 25 March - 12:30 - 14:00
(Callelongue Amphitheater)

Jeudi 25 mars - 12:30 - 14:00
(Amphitéâtre Callelongue)

page 20

  In English only / En anglais seulement



HIV, A CHRONIC DISEASE: WHAT PRIORITIES TO MANAGE ? / LE VIH, UNE PATHOLOGIE CHRONIQUE : QUELLES PRIORITÉS À PRENDRE EN CHARGE ?

Thursday 25 March - 17:00 - 18:30
(Callelongue Amphitheater)

Jeudi 25 mars - 17:00 - 18:30
(Amphitéâtre Callelongue)

page 21

EXHIBITION MAP PLAN DE L'EXPOSITION

The exhibition area is located at level 2, hall des pas perdus. /
L'exposition est située au niveau 2, hall des pas perdus.

OPENING HOURS / HORAIRES D'OUVERTURE

Wednesday 24 March / Mercredi 24 mars: 08:00 - 19:30

Thursday 25 March / Jeudi 25 mars: 07:30 - 18:30

Friday 26 March / Vendredi 26 mars: 07:30 - 17:00

COMPANIES / SOCIÉTÉS :

Abbott France

Booth number/ stand : **10**

Boehringer Ingelheim France

Booth Number/ stand : **20**

Cellestis Gmbh

Booth number/ stand : **17**

Gilead

Booth Number/ stand : **07**

ViiV Healthcare

Booth Number/ stand : **18**

Laboratoires Merck Sharp & Dhome

Booth Number/ stand : **19**

Roche

Booth Number/ stand : **08**

Schering Plough

Booth Number/ stand : **06**


Tibotec / Janssen Cilag

Booth Number/ stand : **16**

Wisepress

Booth Number/ stand : **01**

**GOUDES ROOM / SALLE DES GOUDES
POSTERS / COMMUNICATIONS AFFICHÉES**



ABBOTT

Abbott, 120 years of technological and scientific innovations, especially regarding HIV/AIDS

- 1985: 1st AIDS screening test
- 1996: launch of Norvir™
- 2001: launch of Kaletra® caps
- 2006: Kaletra® tablets 200/50 mg
- 2008: Kaletra® tablets 100/25 mg and launch of the blister pack
- 2009: launch of Kaletra® tablets 200/50 mg OAD for naive patients

Abbott, a strong humanitarian commitment

- for the people from the 154 developing countries
- for the children affected by HIV/AIDS

Abbott Found has been supporting more than 600 000 children and families since 7 years (Care and Health Care Education programmes)

Abbott, 120 ans d'histoire jalonnée d'innovations technologiques et scientifiques, notamment concernant le VIH/sida :

- 1985 : 1^{er} test du dépistage du Sida
- 1996 : lancement de Norvir™
- 2001 : lancement de Kaletra® capsule
- 2006 : mise à disposition de Kaletra® comprimé 200/50 mg
- 2008 : mise à disposition de Kaletra® comprimé 100/25 mg et lancement de Kaletra® comprimé 200/50 mg en blister
- 2009 : lancement de Kaletra® comprimé 200/50 mg en OAD chez les patients naïfs

Abbott, un engagement humanitaire fort

- Pour les populations de 154 pays en voie de développement ou à revenus intermédiaires
- Pour les enfants atteints du VIH / Sida

Abbott et sa fondation Abbott Found soutiennent depuis 7 ans plus de 600 000 enfants

et familles par des programmes communautaires (apports de soins, programmes d'éducation et services sociaux)

BOEHRINGER INGELHEIM

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

The Boehringer Ingelheim group is present on HIV Market through two treatments:

- > Viramune ® (névirapine), a Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- > Aptivus ® (tipranavir), a protease inhibitor launched in 2007.

The Boehringer Ingelheim group is also committed in the fight against HIV infection in developing countries due to 3 actions:

- > VIRAMUNE Donation Programme for Prevention of Mother-To-Child-Transmission
- > Adjusted Pricing for chronic treatment (Member of the Accelerating Access Initiative (AAI))
- > Extended access to nevirapine
- > Health Care Supporting Activities

For more information please visit www.boehringer-ingelheim.fr

Le groupe pharmaceutique Boehringer Ingelheim, dont le siège se situe à Ingelheim en Allemagne, figure parmi les 20 premières entreprises du médicament au monde. Le groupe compte 138 filiales dans 47 pays et près de 41 300 employés.

Notre entreprise indépendante à capitaux privés est engagée depuis 1885 dans la recherche et le développement, la fabrication et la commercialisation de produits d'intérêt thérapeutique majeur à usage humain et vétérinaire.

Les laboratoires Boehringer Ingelheim sont présents sur le marché des traitements des infections à VIH à travers deux traitements :

- > Viramune® (névirapine), un inhibiteur non nucléosidique de la transcriptase inverse, mis sur le



marché en 1998 et bénéficiant d'une expérience de 12 ans.

-> Aptivus® (tipranavir), une anti-protéase lancée en 2007.

Les laboratoires Boehringer Ingelheim sont également engagés dans la lutte contre l'infection à VIH dans les pays en voie de développement, grâce à des actions orientées selon 3 axes:

-> Programme de dons,

-> Proposition d'une échelle de prix adapté en fonction du PIB des différents pays concernés

-> Cession de licences aux différents fabricants de génériques agrées par l'OMS

Pour plus d'information, consulter notre site Internet : www.boehringer-ingelheim.fr

CELLESTIS

Cellestis is a listed Australian biotechnology company that is a leader in the detection and control of tuberculosis, with the development of its breakthrough blood test QuantiFERON®-TB Gold In-Tube (QFT™). Cellestis is focused on developing diagnostics tests that measure immune function for diseases with an unmet medical need.

Cellestis Limited est une entreprise de biotechnologie australienne fondée en 2000 à Melbourne (Australie). Elle développe et commercialise le test « QuantiFERON-TB Gold In-Tube® (QFT™) », un test sanguin innovant permettant le dépistage de l'infection tuberculeuse et de la tuberculose maladie. En utilisant QuantiFeron® technology, une méthode brevetée, Cellestis développe des tests diagnostics permettant de mesurer la fonction immunitaire en méthode ELISA.

GILEAD

Combattre les maladies engageant le pronostic vital

Chez Gilead, nous appliquons le meilleur de la recherche biopharmaceutique pour créer des traitements innovants dans la lutte contre le VIH/SIDA, les maladies hépatiques et les atteintes respiratoires et cardiovasculaires sévères.

Surpasser les standards thérapeutiques actuels

Nous recherchons constamment de nouvelles molécules plus puissantes, avec de meilleurs profils de résistances, des indices de tolérance plus favorables et plus simples.

Avec chaque percée thérapeutique, nous tâchons de faire avancer significativement la prise en charge des patients et d'améliorer la vie.

JANSSEN CILAG-TIBOTEC

Tibotec is changing people's lives and improving public health by fighting infectious diseases worldwide. We are achieving this by delivering innovative therapeutic and diagnostic solutions that provide significant benefits to patients. Tibotec recognizes its responsibility to collaborate in the international response to HIV/AIDS, a challenge which cannot be separated from the fight for gender equality and poverty reduction.

Tibotec R&D is dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases of high unmet medical need. Tibotec was established in 1994 by Rudi Pauwels as a drug discovery laboratory. In 1995, Virco was established as a spin-off to improve the management of HIV/AIDS with innovative, new molecular diagnostic tools for HIV resistance testing that would better inform the treatment decisions made by physicians. In April 2002 Tibotec and Virco were acquired by Johnson & Johnson. Under the leadership of Paul Stoffels, Tibotec evolved to a fully integrated pharmaceutical company focusing on the discovery and the development of new drugs for Infectious Diseases.

<http://www.tibotec.com/>

Janssen-Cilag axe son développement dans des domaines thérapeutiques hautement spécialisés qui répondent à des enjeux majeurs en santé : la psychiatrie, l'infectiologie (antibiothérapie et virologie), la cancérologie (hématologie), la dermatologie et la douleur.

Engagé dans l'innovation thérapeutique, Janssen-Cilag va plus loin : le laboratoire vise la prise en charge globale des maladies par un travail pluridisciplinaire. Pour assurer celle-ci, il crée, développe et supporte des actions, des services et des programmes.

A l'écoute de l'ensemble des acteurs de santé : médecins, personnel soignant, patients, société civile..., nos équipes œuvrent pour répondre à leurs attentes en visant la santé de tous. Innovation, écoute et partage des connaissances qui constituent les valeurs clés de Janssen-Cilag

LABORATOIRES MERCK SHARP & DOHME-CHIBRET

Subsidiary of Merck and Co. Inc., Laboratory MSD-Chibret participates in the improvement of the health in the world. With its drugs, vaccines, biological therapies, animal and consumer health products, the Group MSD proposes innovative solutions in more than 140 countries worldwide. Its commitment in favour of the access to healthcare is also made through wide programs of donation and provision of drugs for those who more need it.

MSD, to Live better.

For more information, go on www.merck.com or www.msd-france.com

Filiale de Merck & Co. Inc., les Laboratoires MSD-Chibret participent à l'amélioration de la santé dans le monde. Avec ses médicaments, vaccins, thérapies biologiques, produits de santé animale et grand public, le Groupe MSD propose des solutions innovantes dans plus de 140 pays à travers le monde. Son engagement en faveur de l'accès aux soins se fait également à travers de larges programmes de donation et de mise à disposition de médicaments pour ceux qui en ont le plus besoin.

MSD, Vivre mieux.

Pour plus d'informations, rendez-vous sur www.merck.com ou www.msd-france.com

ROCHE / ROCHE

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche, dont le siège est à Bâle, Suisse, figure parmi les leaders de l'industrie pharmaceutique et diagnostique axée sur la recherche. Numéro un mondial de la biotechnologie, Roche produit des médicaments cliniquement différenciés pour le traitement du cancer, des maladies virales et inflammatoires ainsi que des maladies du métabolisme et du système nerveux central. Roche est aussi le leader mondial du diagnostic in vitro ainsi que du diagnostic histologique du cancer, et une entreprise pionnière dans la gestion du diabète. Sa stratégie des soins personnalisés vise à mettre à disposition des médicaments et des outils diagnostiques permettant d'améliorer de façon tangible la santé ainsi que la qualité et la durée de vie des patients. En 2009, Roche, qui comptait plus de 80 000 employés dans le monde, a consacré à la R&D près de 10 milliards de francs. Son chiffre d'affaires s'est élevé à 49,1 milliards de francs. Genentech, Etats-Unis, appartient entièrement au groupe Roche, qui détient en outre une participation majoritaire au capital de Chugai Pharmaceutical, Japon. Pour de plus amples informations, consulter le site internet du groupe à l'adresse www.roche.com.

Tous les noms de marque mentionnés sont protégés par la loi.

SCHERING PLOUGH

As a part of Merck & Co. Inc., Schering-Plough is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them.

Merck & Co. Be Well.

For more information, visit www.merck.com

Filiale de Merck & Co. Inc., Schering-Plough participe à l'amélioration de la santé dans le monde. Avec nos médicaments, vaccins, thérapies biologiques, produits de santé animale et grand public, nous proposons des solutions innovantes dans plus de 140 pays à travers le monde. Notre engagement en faveur de l'accès aux soins se fait également à travers de larges programmes de donation et de mise à disposition de médicaments pour ceux qui en ont le plus besoin.

Merck & Co. Vivre mieux.

Pour plus d'informations, rendez-vous sur www.merck.com

ViiV HEALTHCARE SAS

ViiV Healthcare is a new specialist HIV company established by Glaxosmithkline (GSK) and Pfizer, committed to delivering advances in treatment and improving access to medicines for people living with HIV/AIDS in Europe and worldwide.

ViiV Healthcare was launched the 3rd of November 2009.

With 10 medicines currently available and a pipeline of seven innovative and targeted medicines, including five compounds in phase II, ViiV Healthcare has 17 molecules in its portfolio to develop as potential new HIV treatments.

ViiV Healthcare SAS was launched the 1st of February in France.

Its team will manage a large group of medicines, stemming from the GSK and Pfizer portfolios : Celsentri® maraviroc, Kivexa® abacavir-lamivudine, Telzir® fosamprenavir, Combivir® lamivudine-zidovudine, Trizivir® abacavir-lamivudine-zidovudine, Ziagen® abacavir, Epivir® lamivudine, Retrovir® zidovudine, Agenerase® amprenavir et Rescriptor® delavirdine.

Medical information: 01 39 17 69 69. infomed@viivhealthcare.com.

ViiV Healthcare est née de la volonté des laboratoires GSK et Pfizer de marquer fortement leur engagement dans la lutte contre le VIH, en créant une société dédiée à la recherche dans ce domaine et au traitement de cette maladie, centrée sur les besoins des patients et engagée dans l'innovation. La société a été créée au niveau mondial en novembre 2009.

Avec 10 médicaments déjà commercialisés et 7 molécules ciblées et innovantes en développement, donc 5 en phase 2, ViiV Healthcare détient un potentiel unique pour le traitement et les stratégies thérapeutiques contre le VIH dans les années à venir.

La filiale française, ViiV Healthcare SAS, a été lancée le 1^{er} février 2010.

Ses équipes sont désormais en charge de l'ensemble des antirétroviraux qui appartenaient aux portefeuilles de GSK et de Pfizer : Celsentri® maraviroc, Kivexa® abacavir-lamivudine, Telzir® fosamprenavir, Combivir® lamivudine-zidovudine, Trizivir® abacavir-lamivudine-zidovudine, Ziagen® abacavir, Epivir® lamivudine, Retrovir® zidovudine, Agenerase® amprenavir et Rescriptor® delavirdine (produit en ATU nominative).

Information médicale : 01 39 17 69 69 ou par mail : infomed@viivhealthcare.com.

WISEPRESS

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting

Wisepress Medical Bookshop
The Old Lamp Works
25 High Path
Merton Abbey
London SW19 2JL UK
Phone: +44 20 8715 1812
Fax: +44 20 8715 1722
bookshop@wisepress.com
www.wisepress.com

A series of horizontal dashed lines for writing, spanning the width of the page.

SPONSORS PARTENAIRES

The Organising Committee would like to thank the following companies for their generous support of the 16 ISHEID.

Le Comité d'Organisation souhaite remercier les sociétés suivantes de leur généreux soutien pour la 16^{ème} édition de l'ISHEID.

SILVER SPONSORS / PARTENAIRES ARGENT



ABBOTT France



BRISTOL-MYERS SQUIBB



GILEAD



la médecine fondée sur les preuves.

LABORATOIRES MERCK SHARP
& DOHME-CHIBRET



SCHERING PLOUGH



TIBOTEC / JANSSEN CILAG

BRONZE SPONSORS / PARTENAIRES BRONZE



BOEHRINGER INGELHEIM



VIVHEALTHCARE

SPONSORS / PARTENAIRES



CELLESTIS



ROCHE



WISEPRESS